An optically active 4,4-di-substituted oxazolidine compound having the formula (I) [structure] wherein R 1 represents a substituted C 1 -C 3 alkyl group, a substituted C 2 -C 3 alkenyl group, a formyl group, a hydroxymethyl group, a group of the formula COOR, a halogenated methyl group, a phosphonium methyl group; R represents a C 1 -C 6 alkyl group, a C 2 -C 6 alkenyl group, a phenyl group or a benzyl group; R 2 represents a C 1 -C 6 alkyl group, a C 3 -C 10 cycloalkyl group, or a phenyl group; R 3 represents a C 2 -C 6 alkanoyl group, a C 1 -C 6 alkyloxycarbonyl group, a benzoyl group, a phenyloxycarbonyl group or a benzyloxycarbonyl group and R 4 represents a C 1 -C 6 alkyl group or a C 2 -C 6 alkenyl group.

Description

44 parts

›TECHNICAL FIELD OF THE INVENTION

The present invention relates to optically active 4,4-di-substituted oxazolidine derivatives and procedures for their preparation. The optically active 4,4-di-substituted oxazolidine derivatives of the present invention have advantage as useful synthetic intermediates in new stereoselective industrial manufacturing methods of optically active α,α-di-substituted α-amino acid derivatives and optically active α,α-di-substituted α-amino alcohol derivatives.

›BACKGROUND OF THE INVENTION

As a method for the preparation of optically active α,α-di-substituted α-amino acid derivatives through optically active 4,4-di-substituted oxazolidine derivatives as a synthetic intermediate, for example, methods described by Dieter Seebach, et al. (refer to non-patent literature 1 and non-patent literature 2) and by Carlos Cativiela, et al. (refer to non-patent literature 3 and non-patent literature 4) have been known.

The method described by Dieter Seebach, et al., however, is an unsuitable method for industrial large-scale synthesis because of the extremely low-temperature reaction conditions needed and, additionally, the yield is low.

On the other hand, the method described by Carlos Cativiela, et al. is a method that includes the processes of diastereoselective alkylation using an optically active cyano ester compound and Sharpless asymmetric oxidation, but in the former process, the low yield, low stereoselectivity and numerous reaction steps are a disadvantage, and in the latter process, the use of a peroxidized compound and numerous reaction steps are a disadvantage, and these procedures are also unsuitable for industrial large-scale synthesis.

Furthermore, optically active 4,4-di-substituted oxazolidine derivatives have been used as a synthetic intermediate for the preparation of glutamate receptor antagonists, which are optically active α,α-di-substituted α-amino acid derivatives, and its usefulness have already been known. Glutamate receptor antagonists have been reported as effective against epilepsy, brain defects following heart bypass surgery and/or transplantation, attack, cerebral ischemia, pain, spinal cord injury, head trauma, hypoxia at birth, cardiac arrest and hypoglycemia-induced damage, anxiety, neurodegenerative diseases, Huntington's chorea, AIDS-induced dementia, eye damage, retinopathy, cognitive deficiency, Parkinson's disease, Alzheimer's disease, multiple sclerosis, or the like (refer to non-patent literature 5 to 7 and patent literature 1).

Additionally, several reports demonstrate that optically active α,α-di-substituted α-amino alcohol derivatives exert an immunosuppressive activity based on a novel mechanism of action (refer to non-patent literatures 8 to 10 and patent literature 2), and the optically active 4,4-di-substituted oxazolidine derivatives of the present invention are considered to be useful synthetic intermediates for the preparation of the optically active α,α-di-substituted α-amino alcohol derivatives.

As the manufacturing method of the substituted methylenephosphonium salt disclosed in the patent literature 2, for example, the following procedure (non-patent literature 11) has been disclosed, and compound (IV′-a) is synthesized from the known compound (IV″-a) through the compound (V-a) as the synthetic intermediate, as shown in the following reaction scheme.

However, this procedure has several disadvantages described below:

(1) In Step 1, methyl iodide, which is a mutagen is used and harmful effects on operators and operational environment are a concern. (2) In Step 2, the heating condition is indispensable for the reaction to proceed, but the compound (V-a) is thermally unstable and, additionally, partially decomposed before initiation of the reaction and, consequently, low production yield and low purity of the compound (IV′-a) thus obtained are disadvantageous. (3) As Step 2 is an equilibrium reaction, it is necessary to remove out of the reaction system trimethylamine generated by the progress of the reaction for the reaction to proceed smoothly. Trimethylamine, however, is a malodorous material, and the necessity of special measures such as an amine trap is disadvantageous. (4) Additionally, in Step 2, long-period heating is needed, and an expensive manufacturing cost, when this method is applied to the industrial manufacturing, becomes a problem. [Non-patent literature 1] Tetrahedron Letters, vol. 25, 2545 (1984) [Non-patent literature 2] Helvetica Chimica Acta, vol. 70, 1194 (1987) [Non-patent literature 3] Tetrahedron, vol. 54, 14963 (1998) [Non-patent literature 4] Journal of Organic Chemistry, vol. 64, 8220 (1999) [Non-patent literature 5] Bioorganic Medicinal Chemistry Letters, vol. 8, 447 (1998) [Non-patent literature 6] Bioorganic Medicinal Chemistry Letters, vol. 8, 925 (1998) [Non-patent literature 7] Journal of Medicinal Chemistry, vol. 41, 1641 (1998) [Non-patent literature 8] Journal of Medicinal Chemistry, vol. 43, 2946 (2000) [Non-patent literature 9] Tetrahedron Letters, vol. 43, 8095 (2002) [Non-patent literature 10] Synthesis, 1667 (2003) [Non-patent literature 11] The Journal of Organic Chemistry, vol. 52, 19 (1987) [Patent literature 1] U.S. Pat. No. 5,578,593 Specification [Patent literature 2] Japanese Patent Publication (Kokai) Number 2003-4599

›DISCLOSURE OF THE INVENTION · 1 of 8

Subject to be Solved by the Invention

The subject of the present invention is to provide less-expensive and more efficient stereoselective procedures for the preparation of optically active α,α-di-substituted α-amino acid derivatives and optically active α,α-di-substituted α-amino alcohol derivatives. Furthermore, by providing said manufacturing procedure of the present invention, it becomes possible to perform practical mass production of glutamate receptor antagonists that are useful for therapy against epilepsy, brain deficit following epilepsy, heart bypass surgery, and transplantation of an organ, attack, ischemic brain, pain, spinal cord injury, head trauma, hypoxia at birth, cardiac failure and hypoglycemic damage, anxiety, neurodegenerative diseases, Huntington's disease, AIDS-induced dementia, eye damage, retinopathy, cognitive disorder, Parkinson's disease, Alzheimer's disease, or multiple sclerosis, or the like; or immunosuppressive agents that are useful for therapy against suppression of rejection symptoms caused by organ transplantation or skin transplantation, or for therapy against autoimmune diseases such as rheumatic arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, lupus erythematosus nephritis, glomerular nephritis, insulin resistant diabetes mellitus, atopic dermatitis, and the like.

Measures to Solve the Subject

The inventors of the present invention have diligently investigated for many years into various procedures for the preparation of α,α-di-substituted α-amino acid derivatives and optically active α,α-di-substituted α-amino alcohol derivatives in order to solve the subject described above, and discovered a synthetic procedure comprising processes through optically active 4,4-di-substituted oxazolidine derivatives shown below and furthermore a preparation procedure by which the substituted-methylenephosphonium salt which is useful as the intermediate can be obtained conveniently in high yield, and consequently, the inventors completed the present invention.

The present invention provides

(1) an optically active 4,4-di-substituted oxazolidine derivative having the general formula (I)

[wherein,

R 1 represents a C 1 -C 3 alkyl group which is substituted with one substituent selected from Substituent group A, a C 2 -C 3 alkenyl group which is substituted with one substituent selected from Substituent group A, a halogenated methyl group, a hydroxymethyl group, a formyl group, a group of formula COOR or a phosphonium methyl group, R represents a C 1 -C 6 alkyl group, a C 2 -C 6 alkenyl group, a phenyl group or a benzyl group, R 2 represents a C 1 -C 6 alkyl group, a C 3 -C 10 cycloalkyl group or a phenyl group, R 3 represents a C 2 -C 6 alkanoyl group, a C 1 -C 6 alkyloxycarbonyl group, a benzoyl group, a phenyloxycarbonyl group or a benzyloxycarbonyl group, R 4 represents a C 1 -C 6 alkyl group or a C 2 -C 6 alkenyl group, Substituent group A represents a phenyl group which may optionally be substituted with from 1 to 3 substituents selected from the group consisting of a halogen atom, a cyano group, a phenyl group, a C 1 -C 8 alkyl group, a C 1 -C 9 alkoxy group and a C 2 -C 8 alkanoyl group, a thienyl group, a N-methylpyrrolyl group or a furanyl group], and preferably (2) an optically active 4,4-di-substituted oxazolidine derivative having the general formula (I) described in (1) wherein R 1 represents a formyl group, (3) an optically active 4,4-di-substituted oxazolidine derivative having the general formula (I) described in (1) wherein R 1 represents a hydroxymethyl group, (4) an optically active 4,4-di-substituted oxazolidine derivative having the general formula (I) described in (1) wherein R 1 represents a group of formula COOR, and R represents a C 1 -C 4 alkyl group, an allyl group, a phenyl group or a benzyl group, (5) an optically active 4,4-di-substituted oxazolidine derivative having the general formula (I) described in (1) wherein R 1 represents a methoxycarbonyl group or an ethoxycarbonyl group, (6) an optically active 4,4-di-substituted oxazolidine derivative having the general formula (I) described in (1) wherein R 1 represents a halogenated methyl group, (7) an optically active 4,4-di-substituted oxazolidine derivative having the general formula (I) described in (1) wherein R 1 represents an iodinated methyl group, (8) an optically active 4,4-di-substituted oxazolidine derivative having the general formula (I) described in (1) wherein R 1 represents a phosphonium methyl group, (9) an optically active 4,4-di-substituted oxazolidine derivative having the general formula (I) described in (1) wherein R 1 represents a methyltriphenylphosphonium iodide, (10) an optically active 4,4-di-substituted oxazolidine derivative having the general formula (I) described in (1) wherein R 1 represents an ethyl group or a vinyl group both of which are substituted with one substituent selected from the group consisting of a 4-bromophenyl group, a 4-iodophenyl group, a 4-octylphenyl group, a 4-heptyloxyphenyl group, a 4-octanoylphenyl group, a thienyl group and a N-methylpyrrolyl group, (11) an optically active 4,4-di-substituted oxazolidine derivative having the general formula (I) described in (1) wherein R 1 represents an ethyl group or a vinyl group both of which are substituted with a N-methylpyrrolyl group, (12) an optically active 4,4-di-substituted oxazolidine derivative having the general formula (I) described in any one of (1) to (11) wherein R 2 represents an isopropyl group, a t-butyl group, a diethylmethyl group, a cyclohexyl group or an adamantyl group, (13) an optically active 4,4-di-substituted oxazolidine derivative having the general formula (I) described in any one of (1) to (11) wherein R 2 represents a t-butyl group, (14) an optically active 4,4-di-substituted oxazolidine derivative having the general formula (I) described in any one of (1) to (13) wherein R 3 represents an acetyl group, a methoxycarbonyl group, an ethoxycarbonyl group, a t-butoxycarbonyl group, a phenyloxycarbonyl group or a benzyloxycarbonyl group, (15) an optically active 4,4-di-substituted oxazolidine derivative having the general formula (I) described in any one of (1) to (13) wherein R 3 represents a methoxycarbonyl group, (16) an optically active 4,4-di-substituted oxazolidine derivative having the general formula (I) described in any one of (1) to (15) wherein R 4 represents a methyl group, and (17) any one of optically active 4,4-di-substituted oxazolidine derivatives having the general formula (I) according to (1) selected from following compounds: 2-t-butyl-4-methyl-1,3-oxazolidine-3,4-dicarboxylic acid 3-t-butyl ester 4-methyl ester, 2-t-butyl-4-methyl-1,3-oxazolidine-3,4-dicarboxylic acid 3-benzyl ester 4-methyl ester, 2-t-butyl-4-methyl-1,3-oxazolidine-3,4-dicarboxylic acid dimethyl ester, 2-t-butyl-4-methyl-1,3-oxazolidine-3,4-dicarboxylic acid 3-ethyl ester 4-methyl ester, 3-acetyl-2-t-butyl-4-methyl-1,3-oxazolidine-4-carboxylic acid methyl ester, 2-t-butyl-4-methyl-1,3-oxazolidine-3,4-dicarboxylic acid 3-phenyl ester 4-methyl ester, 3-benzoyl-2-t-butyl-4-methyl-1,3-oxazolidine-4-carboxylic acid methyl ester, 2-t-butyl-4-hydroxymethyl-4-methyl-1,3-oxazolidine-3-carboxylic acid t-butyl ester, 2-t-butyl-4-hydroxymethyl-4-methyl-1,3-oxazolidine-3-carboxylic acid benzyl ester, 2-t-butyl-4-hydroxymethyl-4-methyl-1,3-oxazolidine-3-carboxylic acid methyl ester, 2-t-butyl-4-hydroxymethyl-4-methyl-1,3-oxazolidine-3-carboxylic acid ethyl ester, (3-acetyl-2-t-butyl-4-methyl-1,3-oxazolidin-4-yl)methanol, 2-t-butyl-4-hydroxymethyl-4-methyl-1,3-oxazolidine-3-carboxylic acid phenyl ester, (3-benzoyl-2-t-butyl-4-methyl-1,3-oxazolidin-4-yl)methanol, 2-t-butyl-4-formyl-4-methyl-1,3-oxazolidine-3-carboxylic acid t-butyl ester, 2-t-butyl-4-formyl-4-methyl-1,3-oxazolidine-3-carboxylic acid benzyl ester, 2-t-butyl-4-formyl-4-methyl-1,3-oxazolidine-3-carboxylic acid methyl ester, 2-t-butyl-4-formyl-4-methyl-1,3-oxazolidine-3-carboxylic acid ethyl ester, 3-acetyl-2-t-butyl-4-methyl-1,3-oxazolidine-4-carbaldehyde, 2-t-butyl-4-formyl-4-methyl-1,3-oxazolidine-3-carboxylic acid phenyl ester, 3-benzoyl-2-t-butyl-4-methyl-1,3-oxazolidine-4-carbaldehyde, 2-t-butyl-4-methyl-4-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1,3-oxazolidine-3-carboxylic acid t-butyl ester, 2-t-butyl-4-methyl-4-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1,3-oxazolidine-3-carboxylic acid benzyl ester, 2-t-butyl-4-methyl-4-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1,3-oxazolidine-3-carboxylic acid methyl ester, 2-t-butyl-4-methyl-4-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1,3-oxazolidine-3-carboxylic acid phenyl ester, 2-t-butyl-4-methyl-4-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1,3-oxazolidine-3-carboxylic acid ethyl ester, 3-acetyl-2-t-butyl-4-methyl-4-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1,3-oxazolidine, and 3-benzoyl-2-t-butyl-4-methyl-4-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1,3-oxazolidine.

›DISCLOSURE OF THE INVENTION · 2 of 8

Furthermore, the present invention provides

(18) a procedure for the preparation of a compound having the general formula (Ia) shown below by reacting a compound having the general formula (II) shown below with a compound having the general formula (III) in the presence of a base and a coordinating reagent in the presence or absence of a solvent,

[wherein,

R represents a C 1 -C 6 alkyl group, a C 2 -C 6 alkenyl group, a phenyl group or a benzyl group, R 2 represents a C 1 -C 6 alkyl group, a C 3 -C 10 cycloalkyl group or a phenyl group, R 3 represents a C 2 -C 6 alkanoyl group, a C 1 -C 6 alkyloxycarbonyl group, a benzoyl group, a phenyloxycarbonyl group or a benzyloxycarbonyl group]

R 4 -Z (III)

[wherein,

R 4 represents a C 1 -C 6 alkyl group or a C 2 -C 6 alkenyl group, Z represents a halogen atom or a group having the general formula —O—S(O) 2 R c , and R c represents a methoxyl group, a C 1 -C 6 alkyl group which may optionally be substituted with from 1 to 3 halogen atoms or a phenyl group which may optionally be substituted with from 1 to 3 substituents selected from the group consisting of a halogen atom and a methyl group]

[wherein,

R, R 2 , R 3 and R 4 have the same meanings as those indicated hereinbefore], (19) a procedure for the preparation of a compound having the general formula (Ia) according to (18) wherein the halogen atom represents a bromine atom or an iodine atom, (20) a procedure for the preparation of a compound having the general formula (Ia) according to any one of (18) and (19) wherein the coordinating reagent employed is one reagent or at least two reagents selected from the group consisting of DMPU, DMI, NMP, DMAc, DMF, DMSO, diglyme, triglyme and tetraglyme, (21) a procedure for the preparation of a compound having the general formula (Ia) according to any one of (18) and (19) wherein the coordinating reagent employed is triglyme or tetraglyme, (22) a procedure for the preparation of a compound having the general formula (Ia) according to any one of (18) to (21) wherein the base employed is one base or at least two bases selected from the group consisting of LHMDS, LDA, SHMDS, KHMDS and potassium t-butoxide, (23) a procedure for the preparation of a compound having the general formula (Ia) according to any one of (18) to (21) wherein the base employed is potassium t-butoxide, (24) a procedure for the preparation of a compound having the general formula (Ia) according to any one of (18) to (23) wherein the solvent employed is one solvent or at least two solvents selected from the group consisting of tetrahydrofuran, 1,3-dioxolane, 1,4-dioxane and 1,2-dimethoxyethane, (25) a procedure for the preparation of a compound having the general formula (Ia) according to any one of (18) to (23) wherein the solvent employed is tetrahydrofuran or 1,2-dimethoxyethane, (26) a procedure for the preparation of a compound having the general formula (Ia) according to any one of (18) to (25) wherein the reaction temperature is between −25° C. and 10° C., (27) a procedure for the preparation of a compound having the general formula (Ia) according to any one of (18) to (26) wherein the base is added to the resulting mixture prepared by addition of the coordinating reagent, the compound having the general formula (U) and the compound having the general formula (III) to the solvent, (28) a procedure for the preparation of a compound having the general formula (Ib) shown below by reacting a compound having the general formula (Ia) shown below with a reducing reagent in a solvent,

[wherein

[wherein,

R 2 , R 3 and R 4 have the same meanings as those indicated hereinbefore] (29) a procedure for the preparation of a compound having the general formula (Ib) according to (28) wherein the reducing agent employed is a combination of potassium borohydride and lithium chloride, (30) a procedure for the preparation of a compound having the general formula (Ic) shown below by reacting a compound having the general formula (Ib) shown below with an oxidizing agent in a solvent,

[wherein,

R 2 represents a C 1 -C 6 alkyl group, a C 3 -C 10 cycloalkyl group or a phenyl group, R 3 represents a C 2 -C 6 alkanoyl group, a C 1 -C 6 alkyloxycarbonyl group, a benzoyl group, a phenyloxycarbonyl group or a benzyloxycarbonyl group, and R 4 represents a C 1 -C 6 alkyl group or a C 2 -C 6 alkenyl group]

[wherein,

R 2 , R 3 and R 4 have the same meanings as those indicated hereinbefore] (31) a procedure for the preparation of a compound having the general formula (Ic) according to (30) wherein the oxidizing agent employed is a combination of TEMPO, sodium bromide, sodium hypochloride and sodium hydrogencarbonate, (32) a procedure for the preparation of a compound having the general formula (Ic) shown below by reacting a compound having the general formula (Ia) shown below with a reducing agent in a solvent,

[wherein,

R 2 , R 3 and R 4 have the same meanings as those indicated hereinbefore] (33) a procedure for the preparation of a compound having the general formula (Ic) according to (32) wherein the reducing agent employed is sodium bis(2-methoxyethoxy)aluminum hydride, (34) a procedure for the preparation of a compound having the general formula (Id) shown below by conducting a condensation reaction between a compound having the general formula (Ic) shown below and a compound having the general formula (IV) shown below in the presence of a base in a solvent, followed by hydrogenating the product thus obtained,

›DISCLOSURE OF THE INVENTION · 3 of 8

[wherein,

W represents a phosphonium salt or a phosphonic acid ester, X represents a vinylene group, a sulfur atom, a nitrogen atom substituted with a methyl group and a C 1 -C 6 alkyl group, a nitrogen atom substituted with a silyl group, a nitrogen atom substituted with an acyl group or an oxygen atom, and Y represents a hydrogen atom, a halogen atom, a cyano group, a C 1 -C 8 alkyl group, a C 1 -C 8 alkoxyl group or a C 2 -C 8 alkanoyl group]

[wherein,

R 2 , R 3 , R 1 , X and Y have the same meanings as those indicated hereinbefore] (35) a procedure for the preparation of a compound having the general formula (Id) according to (34) wherein W is triphenylphosphonium iodide, (36) a procedure for the preparation procedure of a compound having the general formula (Id) according to (34) or (35) wherein a base employed is potassium t-butoxide, (37) a procedure for the preparation of a compound having the general formula (Id) shown below by conducting successively a conversion of a compound having the general formula (Ib) shown into a compound having the general formula (V) shown below according to a conventional method, condensation of the product thus obtained with a compound having the general formula (VI) shown below in the presence of a base in a solvent, and the hydrogenation of the product thus obtained,

[wherein,

R 2 , R 3 and R 4 have the same meanings as those indicated hereinbefore, and W represents a phosphonium salt or a phosphonic acid ester]

[wherein,

X represents a vinylene group, a sulfur atom, a nitrogen atom substituted with a C 1 -C 6 alkyl group, a nitrogen atom substituted with a silyl group, a nitrogen atom substituted with an acyl group or an oxygen atom, and Y represents a hydrogen atom, a halogen atom, a cyano group, a C 1 -C 8 alkyl group, a C 1 -C 8 alkoxyl group or a C 2 -C 8 alkanoyl group]

[wherein,

R 2 , R 3 , R 4 , X and Y have the same meanings as those indicated hereinbefore] and (38) a procedure for the preparation of a compound having the general formula (Id) according to (37) wherein W is triphenylphosphonium iodide. Additionally, the present invention provides (39) a procedure for the preparation of a compound having the general formula (IV′) shown below which is characterized by reacting a compound having the general formula (IV″) or a salt thereof with a compound having the general formula (A) in the presence of a compound having the general formula (B) in a solvent,

[wherein,

R 5 represents a C 1 -C 6 alkyl group which may optionally be substituted with substituent(s) selected from Substituent group α or a 5- to 10-membered aromatic group which may optionally be substituted with substituent(s) selected from Substituent group α, or two R 5 groups together with the nitrogen atom to which they are bound form a 4- to 8-membered nitrogen-containing heterocyclic group which may optionally be substituted with substituent(s) selected from Substituent group α, X represents a vinylene group, a sulfur atom, a nitrogen atom substituted with a C 1 -C 6 alkyl group, a nitrogen atom substituted with a silyl group, a nitrogen atom substituted with an acyl group or an oxygen atom, Y represents a hydrogen atom, a halogen atom, a cyano group, a C 1 -C 8 alkyl group, a C 1 -C 8 alkoxyl group or a C 2 -C 8 alkanoyl group, and Substituent group α represents a halogen atom, a cyano group, a C 1 -C 8 alkyl group, a C 1 -C 8 alkoxyl group, a C 1 -C 8 alkylthio group and an acyl group]

[wherein,

R 6 represents a C 1 -C 6 alkyl group which may optionally be substituted with substituent(s) selected from Substituent group α, a C 1 -C 6 alkoxyl group which may optionally be substituted with substituent(s) selected from Substituent group α, a 5- to 10-membered aromatic group which may optionally be substituted with substituent(s) selected from Substituent group α, or a 5- to 10-membered aromatic-oxy group which may optionally be substituted with substituent(s) selected from Substituent group α, and Substituent group α has the same meaning as that described above]

R 7 —V (B)

[wherein,

R 7 represents an acyl group, V represents a halogen atom or a group having the general formula —O—S(O) 2 R c , and R c represents a methoxyl group, a C 1 -C 6 alkyl group which may optionally be substituted with from 1 to 3 halogen atoms or a phenyl group which may optionally be substituted with from 1 to 3 substituents selected from the group consisting of a halogen atom and a methyl group]

[wherein,

R 6 , V, X and Y have the same meanings as those described above] (40) a procedure for the preparation of a compound having the general formula (IV′) according to (39) wherein X represents a nitrogen atom substituted with a methyl group, (41) a procedure for the preparation of a compound having the general formula (IV′) according to (39) or (40) wherein Y represents a hydrogen atom, a C 1 -C 6 alkyl group or a C 1 -C 6 alkoxyl group, (42) a procedure for the preparation procedure of a compound having the general formula (IV′) according to any one of (39) to (41) wherein R 5 represents a C 1 -C 6 alkyl group or two R 5 groups together with the nitrogen atom to which they are bound form a pyrrolidine or piperidine group, (43) a procedure for the preparation of a compound having the general formula (IV′) according to any one of (39) to (42) wherein R 6 represents a phenyl group, (44) a procedure for the preparation of a compound having the general formula (IV′) according to any one of (39) to (43) wherein R 7 represents a C 1 -C 6 alkylcarbonyl group, and (45) a procedure for the preparation of a compound having the general formula (Id) by condensing a compound having the general formula (IV′), which is prepared by reacting a compound having the general formula (IV″) or a salt thereof with a compound having the general formula (A) in the presence of a compound having the general formula (B) in a solvent, with a compound of the general formula (Ic) in the presence of a base in a solvent, followed by hydrogenation of the product thus obtained;

›DISCLOSURE OF THE INVENTION · 4 of 8

[wherein,

R 6 represents a C 1 -C 6 -alkyl group which may optionally be substituted with substituent(s) selected from Substituent group α, a C 1 -C 6 alkoxyl group which may optionally be substituted with substituent(s) selected from Substituent group α, a 5- to 10-membered aromatic group which may optionally be substituted with substituent(s) selected from Substituent group α, or a 5- to 10-membered aromatic-oxy group which may optionally be substituted with substituent(s) selected from Substituent group α, and Substituent group α has the same meaning as that described above]

R 7 —V (B)

[wherein,

R 6 , V, X and Y have the same meanings as those described above]

[wherein,

R 2 , R 3 , R 4 , X and Y have the same meanings as those indicated hereinbefore].

In the general formula (I), the “C 1 -C 3 alkyl group” in the definition of R 1 can be, for example, a methyl, ethyl, 2-methylethyl or n-propyl group, and is preferably an ethyl group.

In the general formula (I), the “C 2 -C 3 alkenyl group” in the definition of R 1 can be, for example, a vinyl, 2-methylvinyl or n-propenyl group, and is preferably a vinyl group.

In the general formula (I), the “C 1 -C 6 alkyl group” in the definitions of R, R 2 and R 4 can be, for example, a methyl, ethyl, n-propyl, i-propyl, n-butyl, isobutyl, s-butyl, t-butyl, n-pentyl, diethylmethyl, 2-methylbutyl, neopentyl, 1-ethylpropyl, n-hexyl, isohexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl or 2-ethylbutyl group, and is preferably a C 1 -C 4 alkyl group, and more preferably R and R 4 are a methyl group and R 2 is a t-butyl group.

In the general formula (I), the “C 2 -C 6 alkenyl group” in the definitions of R and R 4 can be, for example, a vinyl, allyl, 1-methyl-2-propenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 2-methyl-2-propenyl, 2-ethyl-2-propenyl, 1-butenyl, 2-butenyl, 1-methyl-2-butenyl, 1-methyl-1-butenyl, 3-methyl-2-butenyl, 1-ethyl-2-butenyl, 3-butenyl, 1-methyl-3-butenyl, 2-methyl-3-butenyl, 1-ethyl-3-butenyl, 1-pentenyl, 2-pentenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-pentenyl, 1-methyl-3-pentenyl, 2-methyl-3-pentenyl, 4-pentenyl, 1-methyl-4-pentenyl, 2-methyl-4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl or 5-hexenyl group, and is preferably a C 1 -C 4 alkenyl group and more preferably a vinyl group or an allyl group.

In the general formula (I), the “C 3 -C 10 cycloalkyl group” in the definition of R 2 can be, for example, a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl or adamantyl group, and is preferably a C 5 -C 10 cycloalkyl group and more preferably a cyclohexyl group or an adamantyl group.

In the general formula (I), the “C 2 -C 6 alkanoyl group” in the definition of R 3 can be, for example, an acetyl, propionyl, isopropionyl, n-butanoyl, isobutanoyl, n-pentanoyl, isopentanoyl, 2-methylbutanoyl, pivaloyl, n-hexanoyl, 2-methylpentanoyl, 3-methylpentanoyl or hexanoyl group, and is preferably a C 2 -C 4 alkanoyl group and more preferably an acetyl group.

In the general formula (I), the “C 1 -C 6 alkyloxycarbonyl group” in the definition of R 3 can be, for example, a methoxycarbonyl, ethoxycarbonyl, propyloxycarbonyl, n-butoxycarbonyl t-butoxycarbonyl, pentyloxycarbonyl or hexyloxycarbonyl group, and is preferably a C 1 -C 4 alkyloxycarbonyl group and more preferably a methoxycarbonyl group.

In the formulae shown above, the “halogen atom” in the definitions of Substituent groups A and Y can be, for example, a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.

In the formulae shown above, the “C 1 -C 8 alkyl group” in the definitions of Substituent groups A and Y can be, for example, a group shown as the “C 1 -C 6 alkyl group” in the definitions described above, a heptyl group or an octyl group, and is preferably a C 6 -C 8 alkyl group and more preferably an octyl group.

In the formulae shown above, the “C 1 -C 8 alkoxyl group” in the definitions of Substituent groups A and Y can be, for example, a methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, s-butoxy, t-butoxy, n-pentyloxy, isopentyloxy, 2-methylbutoxy, neopentyloxy, 1-ethylpropoxy, n-hexyl, isohexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyloxy, 1-methylpentyloxy, 3,3-dimethylbutoxy, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutoxy, 2,3-dimethylbutoxy, 2-ethylbutoxy, heptyloxy or octyloxy group, and preferably a C 6 -C 8 alkoxyl group and more preferably a heptyloxy group.

›DISCLOSURE OF THE INVENTION · 5 of 8

In the formulae shown above, the “C 2 -C 8 alkanoyl group” in the definitions of Substituent groups A and Y can be, for example, a group shown as the “C 2 -C 6 alkanoyl group” in the definitions described above, a heptanoyl group or an octanoyl group, and is preferably a C 6 -C 8 alkanoyl group and more preferably an octanoyl group.

In the formulae shown above, the “phosphonium salt” in the definition of W can be, for example, trimethylphosphonium chloride, trimethylphosphonium bromide, trimethylphosphonium iodide, triethylphosphonium chloride, triethylphosphonium bromide, triethylphosphonium iodide, tripropylphosphonium chloride, tripropylphosphonium bromide, tripropylphosphonium iodide, tributylphosphonium chloride, tributylphosphonium bromide, tributylphosphonium iodide, triphenylphosphonium chloride, triphenylphosphonium bromide or triphenylphosphonium iodide, and is preferably triphenylphosphonium chloride.

In the formulae shown above, the “phosphonic acid ester” in the definition of W can be, for example, dimethyl phosphonate, diethyl phosphonate, ditrifluoroethyl phosphonate, diphenyl phosphonate, or di-o-tolyl phosphonate, and is preferably diethyl phosphonate.

In the formulae shown above, the “C 1 -C 6 alkyl group” in the definition of X can be, for example, a methyl, ethyl, n-propyl, i-propyl, n-butyl, isobutyl, s-butyl, t-butyl, n-pentyl, diethylmethyl, 2-methylbutyl, neopentyl, 1-ethylpropyl, n-hexyl, isohexyl, 4-methylpentyl, 3-methylpentyl, 2-methylpentyl, 1-methylpentyl, 3,3-dimethylbutyl, 2,2-dimethylbutyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl or 2-ethylbutyl group, and is preferably a C 1 -C 4 alkyl group, and more preferably a methyl group.

In the formulae shown above, the “silyl group” in the definition of X can be, for example, a trimethylsilyl, triethylsilyl, isopropyldimethylsilyl, t-butyldimethylsilyl, methyldiisopropylsilyl, methyldi-t-butylsilyl, triisopropylsilyl, methyldiphenylsilyl, isopropyldiphenylsilyl, butyldiphenylsilyl or phenyldiisopropylsilyl group, and is preferably a trimethylsilyl, triethylsilyl, isopropyldimethylsilyl or t-butyldimethylsilyl group.

In the formulae shown above, the “acyl group” in the definition of X can be, for example, a formyl, carboxyl, carbamoyl, C 1 -C 6 alkylcarbonyl (for example, an acetyl, butanoyl, isobutanoyl or isopentanoyl group), C 1 -C 6 alkoxycarbonyl (for example, a methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl or t-butoxycarbonyl group), C 6 -C 14 arylcarbonyl (for example, a benzoyl, 1-naphthoyl or 2-naphthoyl group), C 6 -C 14 aryloxycarbonyl (for example, a phenyloxycarbonyl or naphthyloxycarbonyl group), C 7 -C 13 aralkyloxycarbonyl (for example, a benzyloxycarbonyl or phenethyloxycarbonyl group), mono- or di-C 1 -C 6 alkylcarbamoyl the alkyl group(s) of which may optionally be substituted with from 1 to 3 substituents selected from the group consisting of a halogen atom and a C 1 -C 6 alkoxycarbonyl group (for example, a methylcarbamoyl, ethylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl, propylcarbamoyl or trifluoroethylcarbamoyl group), C 6 -C 14 arylcarbamoyl (for example, a phenylcarbamoyl group), C 3 -C 10 cycloalkylcarbamoyl (for example, a cyclopropylcarbamoyl group), C 7 -C 13 aralkylcarbamoyl (for example, a benzylcarbamoyl group), C 1 -C 6 alkylsulfonyl (for example, a methylsulfonyl group), C 6 -C 14 arylsulfonyl (for example, a phenylsulfonyl group), nitrogen-containing heterocyclic-carbonyl which may optionally be substituted with a hydroxyl group, (for example, a pyrrolidinylcarbonyl or piperidinocarbonyl group), C 1 -C 6 alkylsulfinyl (for example, a methylsulfinyl group), C 1 -C 6 alkoxycarbamoyl (for example, a methoxycarbamoyl group), aminocarbamoyl, hydroxycarbampyl or thiocarbampyl group, and is preferably a formyl, C 1 -C 6 alkylcarbonyl, C 1 -C 6 alkoxycarbonyl, C 6 -C 14 arylcarbonyl, C 7 -C 13 aralkyloxycarbonyl group and more preferably an acetyl, methoxycarbonyl, ethoxycarbonyl, benzoyl or benzyloxycarbonyl group.

In the formulae shown above, X is preferably a vinylene group, a sulfur atom or a nitrogen atom substituted with a C 1 -C 6 alkyl group and more preferably a vinylene group, a sulfur atom or a nitrogen atom substituted with a methyl group.

In the formulae shown above, Y is preferably a hydrogen atom, a halogen atom, a C 1 -C 8 alkyl group, a C 1 -C 8 alkoxyl group or a C 2 -C 8 alkanoyl group and more preferably a hydrogen atom, a halogen atom, a methyl group, an octyl group, a methoxyl group or a heptyloxy group.

The definition of each substituent of compounds having general formulae (IV′), (IV″), (A) and (B) of the present invention is described in detail below.

The “C 1 -C 6 alkyl group” of the “C 1 -C 6 alkyl group which may optionally be substituted with substituent(s) selected from Substituent group α” in the definitions of R 5 can be, for example, a methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl or 2-ethylbutyl group, and is preferably a methyl, ethyl, propyl, isopropyl, butyl or isobutyl group, and more preferably a methyl or ethyl group.

The “which may optionally be substituted with substituent(s) selected from Substituent group α” of the “C 1 -C 6 alkyl group which may optionally be substituted with substituent(s) selected from Substituent group α” described above means that substitutable positions of said C 1 -C 6 alkyl group may optionally be substituted with from 1 to 3 substituents selected from Substituent group α.

The “5- to 10-membered aromatic ring” of the “5- to 10-membered aromatic group which may optionally be substituted with substituent(s) selected from Substituent group α” in the definition of R 5 shown above is, for example, a 5- to 10-membered aromatic hydrocarbon ring or a 5- to 10-membered aromatic heterocyclic ring. A 5- to 10-membered aromatic hydrocarbon ring is preferably a benzene ring or a naphthalene ring, and more preferably a benzene ring. On the other hand, a 5- to 10-membered aromatic heterocyclic ring is preferably a 5- to 10-membered aromatic heterocyclic ring which contains 1 to 4 heteroatoms selected from the group consisting of an oxygen, sulfur and nitrogen atom in addition to the carbon atoms as the ring-composing atoms, and is, for example, furan, thiophene, pyrrole, oxazole, isoxazole, thiazole, isothiazole, imidazole, pyrazole, 1,2,3-oxadiazole, furazan, 1,2,3-thiadiazole, 1,2,3-triazole, pyridine, pyridazine, pyrimidine, triazine, benzofuran, isobenzofuran, benzo[b]thiophene, indole, isoindole, 1H-indazole, benzimidazole, benzoxazole, 1,2-benzisoxazole, bonzothiazole, 1,2-benzoisothiazole, 1H-benzotriazole, quinoline or isoquinoline, and more preferably furan or thiophene.

›DISCLOSURE OF THE INVENTION · 6 of 8

The “4- to 8-membered nitrogen-containing heterocyclic group” of the “4- to 8-membered nitrogen-containing heterocyclic group which may optionally be substituted with substituent(s) selected from Substituent group α” is, for example, azetidine, pyrrolidine, piperidine, azepan, morpholine or piperazine, and preferably pyrrolidine or piperidine.

The definition of each substituent of the “Substituent group α” is described below.

The “halogen atom” is, for example, a fluorine, chlorine, bromine or iodine atom.

The “C 1 -C 8 alkyl group” is, for example, a methyl, ethyl, n-propyl, i-propyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 2-ethylbutyl, heptyl or octyl group.

The “C 1 -C 8 alkoxyl group” is a group wherein a terminal of the “C 1 -C 8 alkyl group” shown above is bound to an oxygen atom.

The “C 1 -C 8 alkylthio group” is a group wherein a terminal of the “C 1 -C 8 alkyl group” shown above is bound to a sulfur atom.

The “acyl group” can be, for example, a group of formula —COR 3′ , —CO 2 R 3′ , —SO 2 R 3′ , —SOR 3′ , —PO 3 R 3′ R 4′ , —CO—NR 3a R 4a or —CS—NR 3a R 4a [wherein, R 3′ and R 4′ are the same or different and each represents a hydrogen atom, a hydrocarbon group or a heterocyclic group and R 3a and R 4a groups are the same or different and each represents a hydrogen atom, a hydrocarbon group or a heterocyclic group, or R 3a and R 4a groups together with an adjacent nitrogen atom may form a nitrogen-containing heterocyclic ring].

The “hydrocarbon group” described for R 3′ , R 4′ , R 3a or R 4a is a “C 1 -C 6 alkyl group”, a “C 3 -C 6 cycloalkyl group”, a “C 6 -C 10 aryl group” or a “C 7 -C 13 aralkyl group”.

The “nitrogen-containing heterocyclic ring” formed by R 3a and R 4a groups together with an adjacent nitrogen atom is a 5- to 7-membered nitrogen-containing heterocyclic ring which may contain at least one nitrogen atom and 1 or 2 heteroatoms selected from the group consisting of an oxygen, sulfur and nitrogen atom in addition to the carbon atoms as the ring-composing atoms, and is preferably pyrrolidine, imidazolidine, pyrazolidine, piperidine, piperazine, morpholine or thiomorpholine.

The preferred “acyl group” can be, for example, a formyl, carboxyl, carbamoyl, C 1 -C 6 alkylcarbonyl (for example, an acetyl, butanoyl, isobutanoyl or isopentanoyl group), C 1 -C 6 alkoxycarbonyl (for example, a methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl or t-butoxycarbonyl group), C 6 -C 14 arylcarbonyl (for example, a benzoyl, 1-naphthoyl or 2-naphthoyl group), C 6 -C 14 aryloxycarbonyl (for example, a phenyloxycarbonyl or naphthyloxycarbonyl group), C 7 -C 13 aralkyloxycarbonyl (for example, a benzyloxycarbonyl or phenethyloxycarbonyl group), mono- or di-C 1 -C 6 alkylcarbamoyl the alkyl group(s) of which may optionally be substituted with from 1 to 3 substituents selected from the group consisting of a halogen atom and a C 1 -C 6 alkoxycarbonyl group (for example, a methylcarbamoyl, ethylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl, propylcarbamoyl or trifluoroethylcarbamoyl group), C 6 -C 14 arylcarbamoyl (for example, a phenylcarbamoyl group), C 3 -C 10 cycloalkylcarbamoyl (for example, a cyclopropylcarbamoyl group), C 7 -C 13 aralkylcarbamoyl (for example, a benzylcarbamoyl group), C 1 -C 6 alkylsulfonyl (for example, a methylsulfonyl group), C 6 -C 14 arylsulfonyl (for example, a phenylsulfonyl group), nitrogen-containing heterocyclic-carbonyl which may optionally be substituted with a hydroxyl group (for example, a pyrrolidinylcarbonyl or piperidinocarbonyl group), C 1 -C 6 alkylsulfinyl (for example, a methylsulfinyl group), C 1 -C 6 alkoxycarbamoyl (for example, a methoxycarbamoyl group), aminocarbamoyl, hydroxycarbamoyl or thiocarbamopyl group.

The “C 1 -C 6 alkyl group” of the “C 1 -C 6 alkyl group which may optionally be substituted with substituent(s) selected from Substituent group α” and the “5- to 10-membered aromatic group” of the “5- to 10-membered aromatic group which may optionally be substituted with substituent(s) selected from Substituent group α” in the definition of R 6 described above have the same meanings as those indicated in the definition of R 5 described above.

The “C 1 -C 6 alkoxyl group which may optionally be substituted with substituent(s) selected from Substituent group α” in the definition of R 6 described above is a group wherein a terminal of the “C 1 -C 6 alkyl group which may optionally be substituted with substituent(s) selected from Substituent group α” in the definition of R 5 described above is bound to an oxygen atom.

The “5- to 10-membered aromatic-oxy group which may optionally be substituted with substituent(s) selected from Substituent group α” in the definition of R 6 described above is a group wherein a terminal of the “5- to 10-membered aromatic group which may optionally be substituted with substituent(s) selected from Substituent group α” in the definition of R 5 described above is bound to an oxygen atom.

The “acyl group” in the definition of R 7 described above has the same meaning as the “acyl group” indicated in the definition of Substituent group α, and is preferably a C 1 -C 6 alkylcarbonyl group (for example, an acetyl, butanoyl or isobutanoyl group).

The “C 1 -C 6 alkyl group which may optionally be substituted with from 1 to 3 halogen atoms” in the definition of R c described above can be, for example, a fluoromethyl, difluoromethyl, trifluoromethyl, difluoroethyl or trifluoroethyl group, and preferably a trifluoromethyl group.

The “phenyl group which may optionally be substituted with from 1 to 3 substituents selected from the group consisting of a halogen atom and a methyl group” in the definition of R c described above can be, for example, a 4-fluorophenyl, 4-chlorophenyl, 3,4-dichlorophenyl, 4-methylphenyl or 3,4-dimethylphenyl group, and is preferably a 4-dimethylphenyl group.

R 5 described above is preferably a C 1 -C 10 alkyl group which may optionally be substituted with substituent(s) selected from Substituent group α or a 4- to 8-membered nitrogen-containing heterocyclic group formed by two R 5 groups together with a nitrogen atom to which they are bound which may optionally be substituted with substituent(s) selected from Substituent group α, more preferably a C 1 -C 6 alkyl group, or pyrrolidine or piperidine formed by two R 1 groups together with a nitrogen atom to which two R 5 groups are bound, and still more preferably a methyl or ethyl group, or pyrrolidine or piperidine formed by two R 5 groups together with a nitrogen atom to which they are bound.

›DISCLOSURE OF THE INVENTION · 7 of 8

R 6 described above is preferably a C 1 -C 6 alkyl group or a 5- to 10-membered aromatic ring group, and more preferably a phenyl group.

R 7 described above is preferably a C 1 -C 6 alkylcarbonyl group, and more preferably an acetyl group.

V described above is preferably a chlorine atom, a bromine atom or an iodine atom, and more preferably a chlorine or iodine atom.

X described above is preferably a vinylene group, a sulfur atom or a nitrogen atom substituted with a C 1 -C 6 alkyl group, and more preferably a vinylene group, a sulfur atom or a nitrogen atom substituted with a methyl group.

Y described above is preferably a hydrogen atom, a halogen atom, a C 1 -C 8 alkyl group, a C 1 -C 8 alkoxyl group or C 2 -C 8 alkanoyl group, and more preferably a hydrogen atom, a halogen atom, a methyl group, an octyl group, a methoxyl group or a heptyloxy group.

Substituent group α described above is preferably a halogen atom, a C 1 -C 8 alkyl group, a C 1 -C 8 alkoxyl group or an acyl group, more preferably a C 1 -C 6 alkyl group or a C 1 -C 6 alkoxyl group, and particularly preferably a methyl group or a methoxyl group.

When the compounds of the present invention can form salt thereof, these compounds can be used as their salts. Such a salt is, for example, an inorganic base salt, an organic base salt, an inorganic acid salt, an organic acid salt, or a basic or acidic amino acid salt.

The inorganic base salt is preferably an alkali metal salt such as a sodium salt, potassium salt or the like; an alkaline earth metal salt such as a calcium salt, magnesium salt or the like; an aluminum salt; an ammonium salt or the like.

The organic base salt is preferably a trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, diethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N-dibenzylethylenediamine salt or the like.

The inorganic acid salt is preferably a hydrochloride, a hydrobromide, a nitrate, a sulfate, a phosphate or the like.

The organic acid salt is preferably a formate, an acetate, a trifluoroacetate, a fumarate, an oxalate, a tartrate, a maleate, a citrate, a succinate, a malate, methanesulfonate, benzenesulfonate, p-toluenesulfonate or the like.

The compounds having the general formulae (I), (Ia), (Ib), (Ic) and (Id) of the present invention have an asymmetric carbon atom in their structures, and can exist as optical isomers due to such asymmetric carbon atom. In the present invention, a single optical isomer and mixtures of optical isomers are represented as a single chemical formula (I), (Ia), (Ib), (Ic) or (Id), individually. The present invention encompasses both individual optical isomers and mixtures thereof in any ratio. In the compounds having the general formulae (I), (Ia), (Ib), (Ic) and (Id) of the present invention, an amino group is substituted on the asymmetric carbon atom, and the compounds having the R-absolute configuration are particularly desirable, but the compounds containing the S-isomer are also encompassed in the present invention.

When the compounds of general formulae (I), (Ia), (Ib), (Ic) and (Id) of the present invention are allowed to stand in contact with the atmosphere or recrystallized, they may absorb water or water may attach to them to form a hydrate. Such hydrates are included in the compounds having the general formulae (I), (Ia), (Ib), (Ic) and (Id) of the present invention.

As representative compounds of the present invention having general formulae (I), (Ia), (Ic), and (Id), the compounds shown in from Table 1 to Table 3 can be listed, but the scope of the present invention should not be limited to these compounds.

The meaning of the abbreviations in the following Tables is shown below.

Ac: acetyl group Boc: t-butoxycarbonyl group Bzl: benzoyl group Cbz: benzyloxycarbonyl group cHex: cyclohexyl group Eoc: ethoxycarbonyl group Et: ethyl group Et 2 CH: dimethylmethyl group HepCO: octanoyl group HepO: heptyloxy group iPr: isopropyl group Me: methyl group Moc: methoxycarbonyl group Oct: octyl group Ph: phenyl group PhOCO: phenoxycarbonyl group Pr: propyl group tBu: t-butyl group

Among the above compounds, preferred compounds are the compounds of Exemplification Compound Nos. 1-2, 7-8, 13-14, 19-20, 25-26, 31-32, 37-38, 43-44, 49-50, 55-56, 61-62, 67-68, 73-74, 79-80, 85-86, 91-92, 97-98, 103-104, 109-110, 115-116, 121-122, 127-128, 133-134, 139-140, 145-146, 151-152, 157-158, 163-164, 169-170, 175-176, 181-182, 187-188, 193-194, 199-200, 205-206.

More preferred compounds are the compounds of Exemplification Compound Nos. 1, 7, 13, 19, 25, 31, 37, 43, 49, 55, 61, 67, 73, 79, 85, 91, 97, 103, 109, 115, 121, 127, 133, 139, 145, 151, 157, 163, 169, 175, 181, 187, 193, 199, 205.

Even more preferred compounds are the compounds of

Exemplification compound number 43: 2-t-butyl-4-methyl-1,3-oxazolidine-3,4-dicarboxylic acid 3-t-butyl ester 4-methyl ester Exemplification compound number 49: 2-t-butyl-4-methyl-1,3-oxazolidine-3,4-dicarboxylic acid 3-benzyl ester 4-methyl ester Exemplification compound number 55: 2-t-butyl-4-methyl-1,3-oxazolidine-3,4-dicarboxylic acid dimethyl ester Exemplification compound number 61: 2-t-butyl-4-methyl-1,3-oxazolidine-3,4-dicarboxylic acid 3-ethyl ester 4-methyl ester Exemplification compound number 67: 3-acetyl-2-t-butyl-4-methyl-1,3-oxozolidine-4-carboxylic acid methyl ester Exemplification compound number 73: 2-t-butyl-4-methyl-1,3-oxazolidine-3,4-dicarboxylic acid 3-phenyl ester 4-methyl ester Exemplification compound number 79: 3-benzoyl-2-t-butyl-4-methyl-1,3-oxazolidine-4-carboxylic acid methyl ester.

Among the above compounds, preferred compounds are the compounds of Exemplification Compound Nos. 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, 61, 64, 67, 70, 73, 76, 79, 82, 85, 88, 91, 94, 97, 100, and 103.

More preferred compounds are the compounds of Exemplification Compound Nos. 1, 4, 7, 10, 13, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, 49, 52, 55, 58, and 61.

Even more preferred compounds as the compound of (Ib) of the present invention are the compounds of

›DISCLOSURE OF THE INVENTION · 8 of 8

Exemplification compound number 22: 2-t-butyl-4-hydroxymethyl-4-methyl-1,3-oxazolidine-3-carboxylic acid t-butyl ester, Exemplification compound number 25: 2-t-butyl-4-hydroxymethyl-4-methyl-1,3-oxazolidine-3-carboxylic acid benzyl ester, Exemplification compound number 28: 2-t-butyl-4-hydroxymethyl-4-methyl-1,3-oxazolidine-3-carboxylic acid methyl ester, Exemplification compound number 31: 2-t-butyl-4-hydroxymethyl-4-methyl-1,3-oxazolidine-3-carboxylic acid ethyl ester, Exemplification compound number 34: (3-acetyl-2-t-butyl-4-methyl-1,3-oxazolidin-4-yl)methanol, Exemplification compound number 37: 2-t-butyl-4-hydroxymethyl-4-methyl-1,3-oxazolidine-3-carboxylic acid phenyl ester, Exemplification compound number 40: (3-benzoyl-2-t-butyl-4-methyl-1,3-oxazolidin-4-yl)methanol,

as the compound of (Ic) of the present invention are the compounds of

Exemplification compound number 22: 2-t-butyl-4-formyl-4-methyl-1,3-oxazolidine-3-carboxylic acid t-butyl ester, Exemplification compound number 25: 2-t-butyl-4-formyl-4-methyl-1,3-oxazolidine-3-carboxylic acid benzyl ester, Exemplification compound number 28: 2-t-butyl-4-formyl-4-methyl-1,3-oxazolidine-3-carboxylic acid methyl ester, Exemplification compound number 31: 2-t-butyl-4-formyl-4-methyl-1,3-oxazolidine-3-carboxylic acid ethyl ester, Exemplification compound number 34: 3-acetyl-2-t-butyl-4-methyl-1,3-oxazolidine-4-carboaldehyde, Exemplification compound number 37: 2-t-butyl-4-formyl-4-methyl-1,3-oxazolidine-3-carboxylic acid phenyl ester, and Exemplification compound number 40: 3-benzoyl-2-t-butyl-4-methyl-1,3-oxazolidine-4-carboaldehyde.

Among the above compounds, preferred compounds are the compounds of Exemplification Compound, Nos.:

1-6, 25-30, 49-54, 73-78, 97-102, 121-126, 145-150, 169-174, 193-198, 217-222, 241-246, 265-270, 289-294, 313-318, 337-342, and 361-366.

More preferred compounds are the compounds of Exemplification Compound Nos.:

1-3, 25-27, 49-51, 73-75, 97-99, 121-123, 145-147, 169-171, 193-195, 217-219, 241-243, 265-267, 289-291, 313-315, 337-339, and 361-363.

Even more preferred compounds are the compounds of

Exemplification compound number 73: 2-t-butyl-4-methyl-4-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1,3-oxazolidine-3-carboxylic acid t-butyl ester, Exemplification compound number 97: 2-t-butyl-4-methyl-4-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1,3-oxazolidine-3-carboxylic acid benzyl ester, Exemplification compound number 121: 2-t-butyl-4-methyl-4-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1,3-oxazolidine-3-carboxylic acid methyl ester, Exemplification compound number 145: 2-t-butyl-4-methyl-4-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1,3-oxazolidine-3-carboxylic acid ethyl ester, Exemplification compound number 169: 2-t-butyl-4-methyl-4-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1,3-oxazolidine-3-carboxylic acid phenyl ester, Exemplification compound number 193: 3-acetyl-2-t-butyl-4-methyl-4-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1,3-oxozalidine, and Exemplification compound number 217: 3-benzoyl-2-t-butyl-4-methyl-4-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1,3-oxazolidine.

›Advantage of the Invention · 1 of 6

The present invention is useful for providing the optically active 4,4-di-substituted oxazolidine derivatives and procedures for their preparation. The preparation procedures of the present invention have excellent advantages in the following respects, compared with the prior art: 1) increase in yield, 2) improvement in stereoselectivity, 3) extremely low-temperature reaction which is unsuitable for industrial large-scale synthesis is not necessary, and 4) column-chromatographic purification of intermediates is not needed in any step of these synthetic processes.

Furthermore, the compounds having the general formula (Id), which are the optically active 4,4-di-substituted oxazolidine derivatives encompassed in the present invention, are useful as synthetic intermediates in the preparation of optically active α,α-di-substituted α-amino acid derivatives having an excellent glutamate receptor antagonistic action or optically active α,α-di-substituted α-amino alcohol derivatives having new immunosuppressive action.

As shown in the following reaction scheme, for example, the compound (VII) described in non-patent literatures 8 and 9 mentioned hereinbefore, an immunosuppressive agent having a new mode action, can be synthesized from the compounds of the general formula (Id) of the present invention [wherein, R 2 and R 3 have the same meanings as those indicated hereinbefore, R 4 represents a methyl group, X represent a vinylene group, and Y represents a heptyloxy group] by removing R 2 and R 3 groups, both of which are protecting groups, by treatment with an acid, a base or the like according to conventional procedures.

Furthermore, according to the present invention, the substituted methylenephosphonium salt which is useful as a synthetic intermediate in the preparation of the compounds having the general formula (Id) and various kinds of medicines can be obtained conveniently in a high yield.

The substituted methylenephosphonium salt having the general formula (IV′-b) or (IV′-c) prepared by the present invention is, for example, as shown in the following reaction scheme, useful as the intermediate in the preparation of immunosuppressive agents having the general formula (VI′-b) or (VI′-c) disclosed in W003/059880.

[In the above reaction scheme, Y represents an ethylene group, a vinylene group, an ethynylene group, a group of formula -E-CH 2 — (wherein, E represents a carbonyl group, a group of formula —CH(OH)—, an oxygen atom, a sulfur atom or a group of formula —NH—), Z represents a single bond, a C 1 -C 10 alkylene group or a C 1 -C 10 alkylene group which has an oxygen atom or a sulfur atom in or at an end of the carbon chain, and R 5 represents a hydrogen atom, a cycloalkyl group, an aryl group or a heterocyclic group]

Additionally, as shown in following reaction scheme, the substituted methylenephosphonium salt having the general formula (IV′-d) prepared by the present invention is useful since the synthetic intermediate (VI-d) in the preparation of the compound having the general formula (VI′-d) disclosed in WO94/08943, which is used as an immunosuppressive agent, can be prepared by reacting this invented compound (IV′-d) with a compound having a formula (D) described in Bioorganic and Medicinal Chemistry, 11 (2003) 2529-2539.

[in above reaction scheme, R c represents a C 1 -C 10 alkyl group or the like, and X represents a halogen atom]

Best Mode for Carrying out the Invention

The compounds of the present invention can be prepared according to the procedures described below.

The compounds employed in the invented procedures are generally known compounds and can be prepared from known compounds according to known procedures, but some of them are commercially available. As the known procedures described above, there are the procedures described, for example, in “Organic Functional Group Preparation”, Second Edition, Academic Press, Inc., 1989, and “Comprehensive Organic Transformations”, VCH Publishers Inc., 1989.

Depending on the reactivity of functional groups, it is necessary to protect these functional groups contained in the starting materials and/or intermediates generated in the reaction processes using suitable protecting groups, that can be removed to convert the protected functional group(s) into said functional group(s) easily, before initiation of the reaction or at the suitable steps. When the functional group(s) are protected by the suitable protecting group(s), the desired compound can be obtained by removing the protecting group(s), if necessary.

Such functional group is, for example, a hydroxyl group, a carboxyl group, a hydroxyl group, a carbonyl group and an amino group, and the protecting groups are found in Green and Wuts: “Protective Groups in Organic Synthesis”, 3rd edition, John Willey and Sons, Inc., 1999, and a suitable protecting group for them can be used depending on the reaction conditions.

The protecting group employed for the carboxyl group is, for example, a C 1 -C 6 alkyl (for example, a methyl, ethyl, propyl, isopropyl, butyl or t-butyl group), C 7 -C 10 aralkyl (for example, a benzyl group), phenyl, trityl, silyl (for example, a trimethylsilyl, triethylsilyl, dimethylphenylsilyl, t-butyldimethylsilyl or t-butyldiethylsilyl group), or C 2 -C 6 alkenyl group (for example, a 1-allyl group). These groups may optionally be substituted with from 1 to 3 halogen atoms (for example, a fluorine, chlorine, bromine or iodine atom), a C 1 -C 6 alkoxyl group (for example, a methoxy, ethoxy or propoxy group), or a nitro group.

The protecting group employed for the hydroxyl group is, for example, a C 1 -C 6 alkyl (for example, a methyl, ethyl, propyl, isopropyl, butyl or t-butyl group), phenyl, trityl, C 7 -C 11 aralkyl (for example, a benzyl group), formyl, C 1 -C 6 alkylcarbonyl (for example, an acetyl or propionyl group), benzoyl, C 7 -C 11 aralkylcarbonyl (for example, a benzylcarbonyl group), 2-tetrahydropyranyl, 2-tetrahydrofuranyl, silyl (for example, a trimethylsilyl, triethylsilyl, dimethylphenylsilyl, t-butyldimethylsilyl or t-butyldiethylsilyl group) or C 2 -C 6 alkenyl group (for example, a 1-allyl group). These groups may optionally be substituted with from 1 to 3 halogen atoms (for example, a fluorine, chlorine, bromine or iodine atom), a C 1 -C 6 alkyl group (for example, a methyl, ethyl or n-propyl group), a C 1 -C 6 alkoxyl group (for example, a methoxy, ethoxy or propoxy group) or a nitro group.

›Advantage of the Invention · 2 of 6

The protecting group employed for the carbonyl group is, for example, a cyclic acetal (for example, 1,3-dioxane) or non-cyclic acetal group (for example, di-C 1 -C 6 alkyl acetal group).

The protecting group employed for the amino group is, for example, a formyl, C 1 -C 6 alkylcarbonyl (for example, an acetyl or propionyl group), C 1 -C 6 alkoxycarbonyl (for example, a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group), benzoyl, C 7 -C 11 aralkylcarbonyl (for example, a benzylcarbonyl group), C 7 -C 14 aralkyloxycarbonyl (for example, a benzyloxycarbonyl or 9-fluorenylmethoxycarbonyl group), trityl, phthaloyl, N,N-dimethylaminomethylene, silyl (for example, a trimethylsilyl, triethylsilyl, dimethylphenylsilyl, t-butyldimethylsilyl or t-butyldiethylsilyl group) or C 2 -C 6 alkenyl group (for example, a 1-allyl group). These groups may optionally be substituted with from 1 to 3 halogen atoms (for example, a fluorine, chlorine, bromine or iodine atom), a C 1 -C 6 alkoxyl group (for example, a methoxy, ethoxy or propoxy group) or a nitro group.

The removal of the protecting groups described above is carried out by known procedures such as procedures using an acid, a base, ultraviolet light, hydrazine, phenylhydrazine, sodium N-methyldithiocarbamate, tetrabutylammonium fluoride, palladium acetate or trialkylsilyl halide (for example, trimethylsilyl iodide or trimethylsilyl bromide) or a reduction procedure.

Method A

The method A is a process for the preparation of a compound having the general formula (Ia).

In the above reaction scheme, R, R 2 , R 3 and R 4 have the same meanings as those indicated hereinbefore.

The compound having the general formula (II) was synthesized according to the procedure described in the literature (Angew. Chem. GE 100, 10, 1988, 1398-1404). In Step A1, the compound having the general formula (VIII) can be prepared by the esterification of (S)-serine (VII), in Step A2, the compound having the general formula (IX) can be prepared by protecting the amino alcohol compound having the general formula (VIII) obtained above with a R 2 -acetal group, and in Step A3, a compound having the general formula (II) can be prepared by protecting the nitrogen atom of the compound having the general formula (IX) obtained above with R 3 .

Furthermore, in Step A4 which is a reaction of the present invention, a compound having the general formula (Ia) can be prepared stereoselectively by reacting a compound having the general formula (II) with an alkylating agent in the presence of a coordinating reagent and a base and in the presence of an inert solvent or absence of a solvent. This process is a modified process of the method by Dieter Seebach et al., and is improved to enable this invented procedure to be applied to industrial large-scale manufacturing.

In the method by Dieter Seebach et al., the compound having the general formula (Ia) is synthesized by adding a base first to the compound of the general formula (II) in which R is a methyl group, R 2 is a t-butyl group and R 3 is a formyl group (this compound is different from the invented compound in respect that R 3 is a formyl group) and followed by addition of an alkylating agent to the resulting mixture, but the desired compound can be obtained only in the yield of about 40 to 70%. In the present invention, however, it was discovered that the compound of the general formula (Ia) can be synthesized in a high yield by addition of each reagent under reaction conditions which are appropriate to the compound of general formula (II), for example, by the addition of an alkylating reagent and a coordinating reagent to the compound of general formula (II) first and followed by the addition of a base to the resulting mixture obtained. Furthermore, in the present invention, various reaction conditions are improved, and the present invention provides several advantages in respect that the extremely low-temperature reaction (about −78° C.), which is an indispensable step in the conventional procedure and additionally unsuitable for the industrial large-scale manufacturing, can be avoided by selection of a suitable base and coordinating reagent, and a compound having the general formula (Ia) can be synthesized in a high yield even at an industrially applicable temperature, for example, at a temperature ranging from −25° C. to 10° C. In contrast to the prior art which is only the results of researches at the academic level, the present process of the present invention is superior to the prior art in respect that the invented procedure is on an industrially utilizable level.

The alkylating agent employed in the above reaction is not particularly restricted provided that it can be generally used in the alkylation of ester-enolates, and can be, for example, methyl chloride, methyl bromide, methyl iodide, methyl methanesusulfonate, methyl trifluoromethanesulfonate, methyl p-toluenesulfonate, dimethyl sulfate, ethyl chloride, ethyl bromide, ethyl iodide, ethyl methanesusulfonate, ethyl trifluoromethanesulfonate, ethyl p-toluenesulfonate, diethyl sulfate, propyl chloride, propyl bromide, propyl iodide, propyl methanesusulfonate, propyl trifluoromethanesulfonate, propyl p-toluenesulfonate or dipropyl sulfate, and is preferably methyl bromide, methyl iodide, ethyl bromide, ethyl iodide, propyl bromide or propyl iodide, and more preferably methyl bromide or methyl iodide.

The coordinating reagents employed in the above reactions can be, for example, a urea such as 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU) or 1,3-dimethyl-2-imidazolidinone (DMI); an amide such as 1-methyl-2-pyrrolidinone (NMP), N,N-dimethylacetamide (DMAc) or N,N-dimethylformamide (DMF); a sulfoxide such as dimethyl sulfoxide (DMSO); a crown ether such as 12-crown-4, 15-crown-5 or 18-crown-6; or an ethylene glycol such as diethylene glycol dimethyl ether (diglyme), triethylene glycol dimethyl ether (triglyme), tetraethylene glycol dimethyl ether (tetraglyme) or polyethylene glycol, and is preferably DMPU, DMI, NMP, DMF, DMSO, triglyme or tetraglyme, and more preferably triglyme or tetraglyme.

›Advantage of the Invention · 3 of 6

The base employed in the above reaction is not particularly restricted provided that it is a low-nucleophilic base, and can be, for example, an alkali metal amide such as lithium bis(trimethylsilyl)amide (LHMDS), lithium diisopropylamide (LDA), sodium bis(trimethylsilyl)amide (SHMDS) or potassium bis(trimethylsilyl)amide (KHMDS); or an alkali-metal alkoxide such as sodium t-butoxide or potassium t-butoxide, and is preferably potassium t-butoxide.

The inert solvent employed in the above reaction is not particularly restricted provided that it has no adverse effect on the reaction, and can be, for example, an ether such as tetrahydrofuran, diethyl ether, t-butylmethyl ether, 1,4-dioxane or dimethoxyethane; an aromatic hydrocarbon such as toluene or xylene; an aliphatic hydrocarbon such as hexane or heptane; or a mixed solvent thereof, and is preferably an ether, and more preferably tetrahydrofuran or methoxyethane.

The reaction temperature employed in the above reaction is different depending on the starting material, the reagent used and the sort of solvent, but is generally between −100° C. and 30° C., preferably between −80° C. and 10° C., and most preferably between −25° C. and 10° C.

The reaction time employed in the above reaction is different depending on the reaction temperature, the starting material, the reagent and the sort of solvent employed, but is generally from 5 minutes to 24 hours, and preferably from 30 minutes to 5 hours.

After the reaction is completed, the desired compound of this reaction can be isolated from the reaction mixture by conventional treatments. The desired compound can be isolated, for example, by neutralization of the reaction mixture, if necessary, or filtration of the reaction mixture when insoluble material is present in the reaction mixture, extraction of the neutralized solution or the filtrate with an organic solvent immiscible with water such as toluene, washing the resulting organic layer with water, separation of the organic layer containing the desired compound, and then evaporation of the organic solvent under reduced pressure.

The product thus obtained, if necessary, can be further isolated and purified by conventional treatments, for example, by recrystallization or reprecipitation, or by conventional procedures generally used in the isolation and purification of organic compounds (for example, absorption column chromatography using a carrier such as silica gel, alumina or Florisil consisting of magnesium and silica gel; partition column chromatography using Sephadex LH-20 (product of Pharmacia Co., Ltd.), Amberlite XAD-11 (product of Rohm & Hass Co., Ltd.) or Diaion HP-20 (product of Mitsubishi Chemicals Co., Ltd.); ion exchange chromatography; or normal phase or reversed phase column chromatography using silica gel or alkylated silica gel, and preferably by column chromatography using silica gel).

Method B

Step B1 is a process for the preparation of a compound having the general formula (Ib).

In the above reaction scheme, R, R 2 , R 3 and R 4 have the same meanings as those indicated hereinbefore.

A compound having the general formula (Ib) can be prepared by reacting a compound having the general formula (Ia) with a reducing agent in an inert solvent.

The reducing agent employed in the above reaction is not particularly restricted provided that it is generally used in the reduction of an ester to a primary alcohol, and can be, for example, a metal salt of borohydride such as lithium borohydride, sodium borohydride or potassium borohydride; a metal salt of aluminum hydride such as lithium aluminum hydride, sodium aluminum hydride or sodium bis(2-methoxyethoxy)aluminum hydride; or a metal hydride such as isobutylaluminum hydride, and these reducing agents described above can be also used as a combination with a lithium halogenide such as lithium chloride, lithium bromide or lithium iodide, or a lanthanide halogenide such as cerium trichloride, samarium trichloride or europium trichloride, and is preferably lithium borohydride, sodium borohydride, potassium borohydride or sodium bis(2-methoxyethoxy)aluminum hydride, or a combination of these reducing agents and a lithium halogenide, more preferably a combination of sodium borohydride or potassium borohydride and a lithium halogenide, and still more preferably a combination of potassium borohydride and lithium chloride.

The inert solvent employed in the above reaction is different depending on the sort of reagents used, but is not particularly restricted provided that it has no adverse effect on the reaction, and can be, for example, an aliphatic hydrocarbon such as hexane or heptane; an aromatic hydrocarbon such as toluene or xylene; a halogenated hydrocarbon such as dichloromethane or 1,2-dichloroethane; an ether such as tetrahydrofuran, diethyl ether or t-butyl methyl ether; an alcohol such as methanol, ethanol or n-propanol; or a mixed solvent of these solvents, and is preferably an aromatic hydrocarbon, an ether or an alcohol, or a mixed solvent of these solvents, and more preferably tetrahydrofuran or toluene, or a mixed solvent of these solvents.

The reaction temperature employed in the above reaction is different depending on the starting material, the reagent used and the sort of solvent, but is generally between −80° C. and 120° C., and preferably between −20° C. and 50° C.

The reaction time employed in the above reaction is different depending on the reaction temperature, the starting material, the reagent used and the sort of solvent employed, but is generally from 5 minutes to 48 hours, and preferably from 30 minutes to 10 hours.

After the reaction is completed, the desired compound of this reaction can be isolated from the reaction mixture and purified in the same manner as those described in the Method A.

Method C

Step C1 is a process for the preparation of a compound having the general formula (Ic).

In the above reaction scheme, R 2 , R 3 and R 4 have the same meanings as those indicated hereinbefore.

›Advantage of the Invention · 4 of 6

A compound having the general formula (Ic) can be prepared by reacting a compound having the general formula (Ib) with an oxidizing agent in an inert solvent.

The oxidizing agent employed in the above reaction is not particularly restricted provided that it is generally used in the oxidation of a primary alcohol to a corresponding aldehyde, and can be, for example, a chromic acid compound such as potassium chromate, chromic acid-sulfuric acid complex or chromic acid-pyridine complex; a combination of a co-oxidizing agent such as a salt of hypochlorous acid, a salt of bromous acid, N-chlorosuccinimide or molecular oxygen and a catalytic amount of 2,2,6,6-tetramethylpiperidinooxy, free radical (TEMPO) and another salt; a reagent used for DMSO oxidation (complex of dimethylsufoxide and dicyclohexylcarbodiimide, oxalyl chloride, acetic anhydride or phosphorus pentoxide, or a complex of pyridine-sulfuric anhydride); a combination of a transition metal catalyst such as a copper complex or a ruthenium complex and molecular oxygen, or a transition metal catalyst and an organic oxidizing agent such as N-methylmorpholinoxide, and is preferably a combination of a co-oxidizing agent and TEMPO and another salt, more preferably a combination of sodium hypochlorite, TEMPO, sodium bromide and sodium hydrogencarbonate.

The inert solvent employed in the above reaction is different depending on the sort of reagents used, but is not particularly restricted provided that it has no adverse effect on the reaction, and when the combination of a salt of hypochlorous acid, TEMPO and other salts is used as the oxidizing agent, the inert solvent employed can be an aliphatic hydrocarbon such as hexane or heptane; an aromatic hydrocarbon such as toluene or xylene; a halogenated hydrocarbon such as dichloromethane or 1,2-dichloroethane; an ester such as ethyl acetate or butyl acetate; or a mixed solvent of the solvents described above and water, and is preferably a mixed solvent of toluene and water.

The reaction temperature employed in the above reaction is different depending on the starting material, the reagent used and the sort of solvent, but is generally between −50° C. and 100° C., and preferably between −10° C. and 20° C.

After the reaction is completed, the desired compound of this reaction can be isolated from the reaction mixture and purified in the same manner as those described in the Method A.

Method D

Step D1 is an alternative procedure to Method C for the preparation of a compound having the general formula (Ic).

In the above reaction scheme, R, R 2 , R 3 and R 4 have the same meanings as those indicated hereinbefore.

In this step, a compound having the general formula (Ic) can be prepared in one step by reacting a compound having the general formula (Ia) with a reducing agent in an inert solvent without passing through a compound having the general formula (Ib).

The reducing agent employed in the above reaction is not particularly restricted provided that it is generally used in a reduction reaction of an ester into an aldehyde, and can be, for example, a metal salt of borohydride such as lithium borohydride, sodium borohydride or potassium borohydride; a metal salt of aluminum hydride such as lithium aluminum hydride, sodium aluminum hydride or sodium bis(2-methoxyethoxy)aluminum hydride; or a metal hydride such as isobutylaluminum hydride, and these reducing agents described above can be also used as a combination with an organic amine such as pyrrolidine or morpholine, and is preferably sodium bis(2-methoxyethoxy)aluminum hydride or a combination thereof with an organic amine, and more preferably sodium bis(2-methoxyethoxy)aluminum hydride.

The reaction temperature employed in the above reaction is different depending on the starting material, the reagent used and the sort of solvent, but is generally between −100° C. and 50° C., and preferably between −50° C. and 20° C.

After the reaction is completed, the desired compound of this reaction can be isolated from the reaction mixture and purified in the same manner as those described in the Method A.

Method E

The method E is a method for the preparation of compounds having the general formulae (Id′) and (Id).

In the above reaction scheme, R, R 2 , R 3 , R 4 , W, X and Y have the same meanings as those indicated hereinbefore.

Step E1 is a process for the preparation of a compound having the general formula (Id′) by reacting a compound having the general formula (Ic) with a compound having the general formula (IV) in the presence of a base in an inert solvent.

The base employed in the above reaction is not particularly restricted provided that it is generally used in the Wittig reaction, and can be, for example, an alkali metal carbonate such as sodium carbonate, potassium carbonate or cesium carbonate; an alkali metal hydride such as lithium hydride or sodium hydride; an alkali metal hydroxide such as sodium hydroxide, potassium hydroxide, barium hydroxide or lithium hydroxide; an alkali metal alkoxide such as sodium methoxide, sodium ethoxide, sodium tert-butoxide or potassium tert-butoxide; an organic base such as 1,8-diazabicyclo[5.4.0]undec-7-ene; an alkyllithium such as butyllithium or an alkylmagnesium halide such as butylmagnesium bromide; an alkali metal amide such as lithium diisopropylamide, lithium bis(trimethylsilyl)amide, sodium bis(trimethylsilyl)amide or potassium bis(trimethylsilyl)amide, and is preferably an alkali metal carbonate, an alkali metal alkoxide or an alkali metal amide, and more preferably potassium carbonate, cesium carbonate, sodium methoxide, sodium ethoxide or potassium tert-butoxide.

›Advantage of the Invention · 5 of 6

The inert solvent employed in the above reaction is not particularly restricted provided that it has no adverse effect on the reaction, and can be, for example, an ether such as tetrahydrofuran, diethyl ether, t-butylmethyl ether; a urea such as 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone or 1,3-dimethyl-2-imidazolidinone; an amide such as 1-methyl-2-pyrrolidinone, N,N-dimethylacetamide or N,N-dimethylformamide; a sulfoxide such as dimethyl sulfoxide; or an alkylnitrile such as acetonitrile, and preferably a urea or an amide, and more preferably N,N-dimethylformamide.

The reaction temperature employed in the above reaction is different depending on the starting material, the reagent used and the sort of solvent, but is generally between −80° C. and 30° C., and preferably between −20° C. and 10° C.

After the reaction is completed, the desired compound of this reaction can be isolated from the reaction mixture and purified in the same manner as those described in the Method A.

Step E2 is a process for the preparation of a compound having the general formula (Id) by reacting a compound having the general formula (Id′) with a reducing agent in an inert solvent. The reduction reaction is preferably carried out with a metal catalyst in a hydrogen atmosphere.

The metal catalyst employed in the above reaction is not particularly restricted provided that it can generally be used for catalytic reduction, and can be, for example, a heterogeneous palladium-type catalyst such as palladium-charcoal, palladium-alumina or palladium-zeolite; a nickel-type catalyst such as Raney nickel; a platinum catalyst such as platinum oxide or platinum-charcoal; a rhodium-type catalyst such as rhodium-aluminum oxide, rhodium-charcoal or triphenylphosphine-rhodium chloride; or a noble metal catalyst other than the catalysts described above such as ruthenium-charcoal, and preferably a heterogeneous palladium-type catalyst such as palladium-charcoal, palladium-alumina or palladium-zeolite.

The pressure of hydrogen employed in the above reaction is generally between 0.1 and 50 atmospheric pressures, and preferably between 1 and 10 atmospheric pressures.

The inert solvent employed in the above reaction is not particularly restricted provided that it has no adverse effect on the reaction, and can be, for example, an aliphatic hydrocarbon such as hexane or heptane; an aromatic hydrocarbon such as toluene or xylene; a halogenated hydrocarbon such as dichloromethane or 1,2-dichloroethane; an ester such as ethyl acetate or butyl acetate; an ether such as tetrahydrofuran, diethyl ether or t-butyl methyl ether; an amide such as 1-methyl-2-pyrrolidinone, N,N-dimethylformamide or N,N-dimethylacetamide; an alcohol such as methanol, ethanol or n-propanol; an organic acid such as formic acid or acetic acid; an aqueous inorganic acid solution such as aqueous hydrochloric acid solution or aqueous sulfuric acid solution; or water; or a mixed solvent of water and solvent(s) described above, and preferably an alcohol, an ether, or a mixed solvent of these solvents and water, and more preferably methanol or ethanol.

The reaction temperature employed in the above reaction is different depending on the starting material, the reagent used and the sort of solvent, but is generally between −20° C. and 100° C., and preferably between 0° C. and 50° C.

After the reaction is completed, the desired compound of this reaction can be isolated from the reaction mixture and purified in the same manner as those described in the Method A.

Method F

Method F is an alternative procedure to Method E for the preparation of a compound having the general formula (Id).

In the above reaction scheme, R, R 2 , R 3 , R 4 , W, X, Y and Z have the same meanings as those indicated hereinbefore.

Step F1 is a process for the preparation of a compound having the general formula (V′) and achieved by reacting a compound having the general formula (Ib) with a halogenating agent or a sulfonylating agent in the presence or absence of a base in an inert solvent.

The halogenating agent employed in the above reaction is not particularly restricted provided that it is generally used for the halogenation of a primary alcohol, and can be, for example, oxalyl chloride; a thionyl halide such as thionyl chloride or thionyl bromide; a phosphorus trihalogenide such as phosphorus trichloride or phosphorus tribromide; a phosphorus pentahalide such as phosphorus pentachloride or phosphorus pentabromide; a phosphorus oxyhalide such as phosphorus oxychloride or phosphorus oxybromide; a Vilsmeier type reagent such N,N-dimethylchloroforminium chloride or N,N-dimethylbromoforminium bromide; a combination of a phosphine such as triphenylphosphine and a halogen atom or a tetrahalogenated methane; or a combination of a phosphine such as a combination of triphenylphosphine, diethyl azodicarboxylate and lithium bromide, an azodicarboxylic acid ester and a halogenated metal, and preferably a combination of triphenylphosphine and iodine.

The sulfonylating agent employed in the above reaction is not particularly restricted provided that it is generally used for sulfonylation reaction, and can be, for example, a sulfonyl halide such as methanesulfonyl chloride or p-toluenesulfonyl chloride, or a sulfonic anhydride, and is preferably methanesulfonyl chloride or p-toluenesulfonyl chloride.

The base employed in the above reaction is different depending on the sort of reagents used, but is not particularly restricted, and can be, for example, an organic base such as imidazole, pyridine, triethylamine or N-methylimidazole, and is preferably as imidazole, pyridine or triethylamine.

›Advantage of the Invention · 6 of 6

The inert solvent employed in the above reaction is different depending on the sort of reagents used, but is not particularly restricted provided that it has no adverse effect on the reaction, and can be, for example, an aliphatic hydrocarbon such as hexane or heptane; an aromatic hydrocarbon such as toluene or xylene; a halogenated hydrocarbon such as dichloromethane or 1,2-dichloroethane; an ester such as ethyl acetate or butyl acetate; an ether such as tetrahydrofuran, diethyl ether or t-butyl methyl ether; or an amide such as 1-methyl-2-pyrrolidinone, N,N-dimethylformamide or N,N-dimethylacetamide, and is preferably toluene.

The reaction time employed in the above reaction is different depending on the reaction temperature, the starting material, the reagent used for the reaction and the sort of solvent employed, but is generally from 5 minutes to 48 hours, and preferably from 1 hour to 10 hours.

The compound having the general formula (V′) in which Z is a halogen group can be prepared by reacting a compound having the general formula (V′) in which Z is a sulfonyl group with a halogenating agent in an inert solvent.

The halogenating agent employed in the above reaction is not particularly restricted provided that it is generally used for halogenation of a compound in which a moiety of primary alcohol is sulfonylated, and can be, for example, a halogenated metal such as lithium chloride, lithium bromide, lithium bromide, sodium bromide, sodium iodide, potassium iodide, zinc chloride, zinc bromide or zinc iodide, and is preferably sodium iodide or potassium iodide.

The inert solvent employed in the above reaction is not particularly restricted provided that it has no adverse effect on the reaction, and can be, for example, an ether such as tetrahydrofuran, diethyl ether or t-butyl methyl ether; an amide such as 1-methyl-2-pyrrolidinone, N,N-dimethylformamide (DMF), or N,N-dimethylacetamide; an alcohol such as methanol, ethanol or n-propanol; or a sulfoxide such as dimethyl sulfoxide, and is preferably DMF.

The reaction time employed in the above reaction is different depending on the reaction temperature, the starting material, the reagent used for the reaction and the sort of solvent employed, but is generally from 30 minutes to 48 hours, and preferably from 1 hour to 10 hours.

After the reaction is completed, the desired compound of this reaction can be isolated from the reaction mixture and purified in the same manner as those described in the Method A.

›Step F2

Step F2 is a process for the preparation of a compound having the general formula (V).

This step is achieved by reacting a compound having the general formula (V′) with a phosphine or a phosphonic acid ester in an inert solvent.

The phosphine employed in the above reaction is not particularly restricted provided that it is generally used for the synthesis of a phosphonium salt, and can be, for example, trimethylphosphine, triethylphosphine, tripropylphosphine, tributylphosphine or triphenylphosphine, and is preferably triphenylphosphine.

The phosphonic acid ester employed in the above reaction is not particularly restricted provided that it is generally used for the synthesis of the phosphonic acid ester, and can be, for example, a phosphonic acid ester indicated in the above-mentioned definition, and is preferably triethyl phosphonate.

The inert solvent employed in the above reaction is not particularly restricted provided that it has no adverse effect on the reaction, and can be, for example, an aliphatic hydrocarbon such as hexane or heptane; an aromatic hydrocarbon such as toluene or xylene; a halogenated hydrocarbon such as dichloromethane or 1,2-dichloroethane; an ester such as ethyl acetate or butyl acetate; an ether such as tetrahydrofuran, diethyl ether or t-butyl methyl ether; an amide such as 1-methyl-2-pyrrolidinone, N,N-dimethylformamide (DMF) or N,N-dimethylacetamide; an alcohol such as methanol, ethanol or n-propanol; a sulfoxide such as dimethyl sulfoxide; a nitrile such as acetonitrile, but depending on the reagent employed, the above reaction can be carried out in the absence of a solvent. The preferred inert solvent is ethyl acetate, DMF or acetonitrile.

After the reaction is completed, the desired compound of this reaction can be isolated from the reaction mixture and purified in the same manner as those described in the Method A.

›Step F3

Step F3 is a process for the preparation of a compound having the general formula (Id′) by reacting a compound having the general formula (V) with a compound having the general formula (VI) in the presence of a base in an inert solvent. Step F3 can be carried out in the same manner as that described in Step E1 of the method E.

The compound having the general formula (Id′) obtained in Step F3 can be converted into a compound having the general formula (Id) in the same manner as that described in Step E2 of the Method E.

Method G

Method G is a process for the preparation of a compound having the general formula (IV′) by reacting a compound having the general formula (IV″) or salt thereof with a compound having the general formula (A) in the presence of a compound having the general formula (B) in a solvent.

In the above reaction scheme, R 5 , R 6 , R 7 , V, X and Y have the same meanings as those indicated hereinbefore.

The amount of the compound having the general formula (A) used is generally from 0.5 to 40.0 molar equivalents of the amount of the compound having the general formula (IV″) or salt thereof used, and preferably from 1.0 to 10.0 molar equivalents.

The amount of the compound having the general formula (B) used is generally from 0.5 to 40.0 molar equivalents of the amount of the compound having the general formula (IV″) or salt thereof used, and preferably from 1.0 to 10.0 molar equivalents.

The reaction of this Step is generally carried out in a solvent. The solvent employed in the above reaction can be, for example, an amide such as N,N-dimethylformamide, N,N-dimethylacetamide or N-methylpyrrolidone; a sulfoxide such as dimethyl sulfoxide; a halogenated hydrocarbon such as chloroform or dichloromethane; an aromatic hydrocarbon such as benzene or toluene; an aliphatic hydrocarbon such as hexane or cyclohexane; an ether such as tetrahydrofuran, dioxane, diethyl ether or dimethoxyethane; an ester such as methyl acetate or ethyl acetate; or a nitrile such as acetonitrile or propionitrile. These solvents may be used in the above reaction as mixtures containing at least two of them in any ratio.

The solvent employed in the above reaction is preferably a mixed solvent of an aromatic hydrocarbon and a nitrile and more preferably a mixed solvent of toluene and acetonitrile.

The reaction temperature employed in the above reaction is generally between −80° C. and 150° C., and preferably between −20° C. and 50° C.

The reaction time employed in the above reaction is generally from 1 minute to 240 hours, and preferably from 10 minutes to 120 hours.

The compound having the general formula (IV′) or salt thereof thus obtained can be isolated and purified by any known procedures for isolation and purification, for example, through evaporation, concentration under reduced pressure, extraction with solvent, crystallization, recrystallization, partitioning between solvent systems, chromatography and the like.

›EXAMPLES

The present invention is described in more detail hereinafter by way of the Examples and the Test examples, but the scope of the present invention should not be limited to these examples.

›Examples24

›Example 1

(2R,4S)-2-t-Butyl-4-methyl-1,3-oxazolidine-3,4-dicarboxylic acid dimethyl ester (Compound Shown as Ia in Table 1: Exemplification Compound Number 55)

To a solution of (2R,4S)-2-t-butyl-1,3-oxazolidine-3,4-dicarboxylic acid dimethyl ester (384 g, 1.57 mol) prepared according to the procedure described in the literature (CHIMICA, 42, 176 (1988)) in tetrahydrofuran (2300 mL) were added successively tetraethylene glycol dimethyl ether (380 mL) and methyl iodide (290 mL, 4.70 mol) under a nitrogen atmosphere with stirring, and the resulting mixture was cooled to about −20° C. Subsequently, to the resulting mixture was added dropwise slowly a solution of potassium t-butoxide (263 g, 2.35 mol) in tetrahydrofuran (1900 mL) below −5° C. under a nitrogen atmosphere with stirring, and the resulting mixture was stirred at about −10° C. for 1 hour. After stirring, a 10% aqueous ammonium chloride solution was added to the reaction mixture with stirring to quench the reaction, and the resulting mixture was extracted with toluene. The extract separated was washed twice with a 5% aqueous sodium chloride solution and evaporated in vacuo to afford the crude product of the title compound (373 g (determined by HPLC), yield: 92%). The crude product thus obtained was used for the following reaction step without further purification. Additionally, it could be possible to obtain the pure title compound by purifying the crude product by chromatography on a silica gel column (eluent: a mixed solvent of ethyl acetate and hexane).

[α] D 27 −9.74 (c 1.001, MeOH). 1 H NMR (CDCL 3 , 400 MHz): δ 0.97 (s, 9H), 1.62 (s, 3H), 3.69 (s, 3H), 3.77 (s, 3H), 3.82 (d, 1H, J=8.3 Hz), 4.28 (d, 1H, J=8.3 Hz), 5.15 (s, 1H). 13 C NMR (CDCL 3 , 100 MHz): δ 21.2, 26.3, 39.0, 52.4, 52.6, 66.5, 76.9, 97.6, 155.1, 172.2. IR νmax (Liquid Film): 2958, 2909, 1737, 1719, 1478, 1443, 1345, 1313, 1282, 1249, 1218, 1195, 1141, 1115, 1059, 1034 cm −1 .

›Example 2

(2R,4R)-2-t-Butyl-4-hydroxymethyl-4-methyl-1,3-oxazolidine-3-carboxylic acid methyl ester (Compound Shown as Ib in Table 2: Exemplification Compound Number 28)

A mixture of lithium chloride (132 g, 3.13 mol), potassium borohydride (168 g, 3.13 mol) and tetrahydrofuran (3800 mL) was stirred at room temperature under a nitrogen atmosphere for 1 hour. Subsequently, to the mixture was added a solution of (2R,4S)-2-t-butyl-4-methyl-1,3-oxazolidine-3,4-dicarboxylic acid dimethyl ester (373 g, 1.44 mol) prepared according to the procedure described in Example 1 in toluene (1150 mL) under a nitrogen atmosphere with stirring, and the resulting mixture was warmed to about 45° C. and furthermore stirred at the same temperature for 3 hours. After stirring, the reaction mixture was cooled in an ice-bath, and to the reaction mixture was added slowly a 10% aqueous ammonium chloride solution with stirring to quench the reaction. The reaction mixture was extracted with toluene, and the extract was washed with water and evaporated in vacuo to afford the crude product of the title compound (327 g (determined by HPLC), yield: 98%,). The crude product thus obtained was used for the following reaction step without further purification. Additionally, it could be possible to obtain the pure title compound by purifying the crude product by chromatography on a silica gel column (eluent: a mixed solvent of ethyl acetate and hexane).

[α] D 27 +12.7 (c 1.009, MeOH). 1 H NMR (CDCL 3 , 400 MHz): δ 0.93 (s, 9H), 1.43 (s, 3H), 3.55 (brd, 1H, J=11.3 Hz), 3.71 (s, 3H), 3.74 (d, 1H, J=8.6 Hz), 3.83 (d, 1H, J=11.3 Hz), 3.87 (brd, 1H, J=8.6 Hz), 5.13 (s, 1H). 13 C NMR (CDCL 3 , 100 MHz): δ 19.5, 26.4, 38.6, 52.5, 65.2, 67.1, 75.8, 97.3, 156.8. IR νmax (Liquid Film): 3440, 2959, 2909, 2875, 1709, 1686, 1479, 1447, 1399, 1358, 1317, 1281, 1196, 1172, 1134, 1112, 1069, 1047, 960, 805, 759 cm −1 .

›Example 3

(2R,4S)-2-t-Butyl-4-formyl-4-methyl-1,3-oxazolidine-3-carboxylic acid methyl ester (Compound Shown as Ic in Table 2: Exemplification Compound Number 28)

To a solution of (2R,4S)-2-t-butyl-4-hydroxymethyl-4-methyl-1,3-oxazolidine-3-carboxylic acid methyl ester (260 g, 1.12 mol) prepared according to the procedure described in Example 2 in toluene (6000 mL) were added successively water (3000 mL), sodium bromide (128 g) and sodium hydrogencarbonate (260 g) with stirring, and the resulting mixture was cooled to about 0° C. Subsequently, to the resulting mixture was added 2,2,6,6-tetramethylpiperidinooxy, free radical (1.94 g, 0.0125 mol) with stirring, and furthermore, to the resulting mixture was added dropwise slowly a 12.7% aqueous sodium hypochlorite solution (748 mL, 1.34 mol) below 5° C. with stirring, and the resulting mixture was furthermore stirred at about 0° C. for 30 minutes. After stirring, ethanol was added to the reaction mixture with stirring, and the resulting mixture was stirred for about 1 hour, and then the reaction was quenched. After partitioning the reaction mixture, the organic layer separated was washed successively with an aqueous sodium thiosulfate solution and water, and evaporated in vacuo to afford the crude product of the title compound (225 g, yield: 87%). The crude product thus obtained was used for the following reaction step without further purification. Additionally, it could be possible to obtain the pure title compound by recrystallization of the crude product from hexane.

[α] D 27 −7.09 (c 1.002, acetonitrile). 1 H NMR (CDCL 3 , 400 MHz): δ 0.98 (s, 9H), 1.48 (s, 3H), 3.67 (d, 1H, J=8.8 Hz), 3.70 (s, 3H), 4.17 (d, 1H, J=8.8 Hz), 5.20 (s, 1H), 9.72 (s, 1H). 13 C NMR (CDCL 3 , 100 MHz): δ 18.1, 26.3, 38.9, 52.7, 70.0, 73.1, 97.3, 155.6, 199.2. IR νmax (KBr): 2982, 2967, 2958, 2938, 2897, 2887, 1737, 1711, 1476, 1443, 1357, 1340, 1307, 1216, 1198, 1181, 1115, 1051, 995, 950, 937 cm −1 .

›Example 4

(2R,4R)-2-t-Butyl-4-methyl-4-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1,3-oxazolidine-3-carboxylic acid methyl ester (Compound Shown as Id in Table 3: Exemplification Compound Number 121)

To a solution of (2R,4S)-2-t-butyl-4-formyl-4-methyl-1,3-oxazolidine-3-carboxylic acid methyl ester (225 g, 0.981 mol) prepared according to the procedure described in Example 3 in N,N-dimethylformamide (1125 mL) was added [(1-methyl-1H-pyrrol-2-yl)methyl]triphenylphosphonium iodide (522 g, 1.08 mol) prepared according the procedure described in the literature (J. Org. Chem., 52, 19 (1987) with stirring, and the resulting mixture was cooled to about −10° C. Subsequently, to the reaction mixture was added dropwise a solution of potassium t-butoxide (132 g, 1.18 mol) in dimethylformamide (125 mL) below 5° C. with stirring, and the resulting mixture was stirred at about 0° C. for about 1 hour. After stirring, water was added to the reaction mixture to quench the reaction, and the reaction mixture was extracted with heptane. The extract was evaporated in vacuo to afford the Wittig reaction product.

Subsequently, to a solution of the Wittig reaction product obtained above in methanol (2250 mL) was added 5% palladium-charcoal (45 g) with shaking, and the resulting mixture was shaken at room temperature under a hydrogen atmosphere for about 1.5 hours. After shaking, the reaction mixture was filtered through a membrane filter (pore diameter: 0.2 μm), and the filtrate was evaporated in vacuo. The residue obtained was recrystallized from a mixed solvent of methanol and water (1:1, v/v) to afford the almost pure title compound (278 g, yield: 92%).

[α] D 27 −12.6 (c 1.001, MeOH). 1 H NMR (CDCL 3 , 400 MHz): δ 0.97 (s, 9H), 1.43 (s, 3H), 2.05 (apparent dt, 1H, J=4.3, 12.8 Hz), 2.39 (apparent dt, 1H, J=4.1, 12.7 Hz), 2.51 (ddd, 1H, J=4.4, 12.4, 14.6 Hz), 2.61 (ddd, 1H, J=4.6, 12.6, 14.5 Hz), 3.55 (s, 3H), 3.69 (s, 1H), 3.70 (d, 3H, J=8.3 Hz), 4.00 (d, 1H, J=8.3 Hz), 5.15 (s, 1H), 5.90 (brs, 1H), 6.05 (s, 1H), 6.53 (brs, 1H). 13 C NMR (DMSO-d 6 , 100 MHz): δ 21.6, 22.1, 26.6, 33.2, 37.2, 38.3, 52.1, 63.7, 77.1, 96.5, 105.1, 106.3, 121.4, 132.3, 156.2. IR νmax (KBr): 2979, 2954, 2921, 2891, 1698, 1493, 1466, 1447, 1351, 1318, 1304, 1168, 1098, 1063, 958, 725 cm −1 .

›Example 5

(2R,4S)-2-Isopropyl-4-methyl-1,3-oxazolidine-3,4-dicarboxylic acid dimethyl ester (Compound Shown as Ia in Table 1: Exemplification Compound Number 13)

(i) (4S)-2-Isopropyl-1,3-oxazolidine-4-carboxylic acid methyl ester

To a suspension of L-serine methyl ester hydrochloride (50.00 g, 321 mmol) in toluene (500 mL) were added successively 2-methylpropanal (35.2 mL, 385 mmol), triethylamine (49.3 mL, 354 mmol) and water-absorbing polymer (2.50 g) under a nitrogen atmosphere with stirring, and the resulting mixture was stirred at 45° C. for 2 hours under the nitrogen atmosphere. After cooling the reaction mixture to 25° C., the insoluble materials were filtered off, and the insoluble materials separated were washed with toluene (250 mL). The filtrate and the washings were combined and evaporated in vacuo to remove toluene, and the residue obtained was purified by distillation under reduced pressure to afford the title compound (97-98° C./10 mm Hg, 44.66 g, yield: 80%).

1 H NMR (CDCl 3 , 400 MHz): δ 0.94 (d, J=6.8 Hz, 3H), 1.01 (d, J=6.8 Hz, 3H), 1.60-1.92 (m, 1H), 2.00-2.45 (m, 1H), 3.72-3.80 (m, 4H), 3.85-4.20 (m, 3H). MS (FAB): m/z 174 (M+H + ). HRMS (FAB): calcd for C 8 H 16 NO 3 (M+H + ): 174.1130. found: 174.1127.

(ii) (2R,4S)-2-Isopropyl-1,3-oxazolidine-3,4-dicarboxylic acid dimethyl ester

A mixture of (4S)-2-isopropyl-1,3-oxazolidine-4-carboxylic acid methyl ester (28.22 g, 163 mmol) synthesized according to the procedure described in Step (i) and toluene (250 mL) was cooled to about 0° C. under a nitrogen atmosphere with stirring. Subsequently, to the mixture was added dropwise methyl chloroformate (21.4 mL, 277 mmol) below 5° C. with stirring under a nitrogen atmosphere, and the resulting mixture was stirred at about 0° C. for 1 hour. After stirring, triethylamine (22.7 mL, 163 mmol) was added dropwise to the reaction mixture, and the resulting mixture was stirred at about 25° C. for 1 hour. After stirring, water (100 mL) was added to the reaction mixture to quench the reaction, and the resulting mixture was partitioned. The organic layer separated was washed with water and evaporated in vacuo to afford the crude product of the title compound (47.25 g, yield: 125%). Additionally, it could be possible to obtain the pure title compound by purifying the crude product by chromatography on a silica gel column (eluent: a mixed solvent of ethyl acetate and hexane).

1 H NMR (CDCl 3 , 400 MHz): δ 0.72 (d, J=6.8 Hz, 3H), 0.97 (d, J=6.8 Hz, 3H), 1.95-2.30 (m, 1H), 3.71 (s, 6H), 4.05-4.18 (m, 2H), 4.38-4.62 (m, 1H), 4.85-5.07 (m, 1H). MS (FAB): m/z 232 (M+H + ), 188, 160. HRMS (ESI): calcd for C 10 H 17 NNaO 5 (M+Na + ): 254.1004. found: 254.1016.

(iii) (2R,4S)-2-Isopropyl-4-methyl-1,3-oxazolidine-3,4-dicarboxylic acid dimethyl ester

Following the procedure mentioned in Example 1, a similar reaction was carried out using (2R,4S)-2-isopropyl-1,3-oxazolidine-3,4-dicarboxylic acid dimethyl ester (36.31 g, 157 mmol) synthesized according to the procedure described in Step (ii) to afford the crude product of the title compound (38.22 g (determined by HPLC), yield: 99%). Additionally, it could be possible to obtain the pure title compound in crystalline form (28.28 g, yield: 73%) by replacing the solvent containing the crude title compound by IsoparE and adjusting the solvent volume to 135 mL, followed by cooling the solution containing the title compound to 0° C.

1 H NMR: (CDCl 3 , 400 MHz) δ 0.92 (d, J=6.8 Hz, 3H), 0.99 (d, J=6.8 Hz, 3H), 1.59 (s, 3H), 2.10-2.58 (m, 1H), 3.37 (s, 3H), 3.55 (s, 3H), 3.78 (d, J=8.2 Hz, 1H), 4.19 (d, J=8.2 Hz, 1H), 4.90-5.12 (m, 1H). MS (FAB): m/z 246 (M+H + ), 202, 174. HRMS (EST): calcd for C 11 H 19 NNaO 5 (M+Na + ): 268.1161. found: 268.1181.

›Example 6

(2R,4S)-2-Isopropyl-4-hydroxymethyl-4-methyl-1,3-oxazolidine-3-carboxylic acid methyl ester (Compound Shown as Ib in Table 2: Exemplification Compound Number 7)

Following the procedure mentioned in Example 2, a similar reaction was carried out using (2R,4S)-2-isopropyl-4-methyl-1,3-oxazolidine-3,4-dicarboxylic acid dimethyl ester (10.00 g, 40.8 mmol) synthesized according to the procedure described in Example 5 to afford the crude product of the title compound (7.62 g (determined by HPLC), yield: 86%). Additionally, it could be possible to obtain the pure title compound by purifying the crude product by chromatography on a silica gel column (eluent: a mixed solvent of ethyl acetate and hexane).

1 H NMR (CDCl 3 , 400 MHz): δ 0.90 (d, J=6.8 Hz, 3H), 0.99 (d, J=6.8 Hz, 3H), 1.41 (s, 3H), 2.05-2.26 (m, 1H), 3.45-3.92 (m, 7H), 5.00 (d, J=4.4 Hz, 1H). MS (FAB): m/z 218 (M+H + ), 186. HRMS (ESI): calcd for C 10 H 9 NNaO 4 (M+Na + ): 240.1212. found: 240.1183.

›Example 7

(2R,4S)-2-Isopropyl-4-formyl-4-methyl-1,3-oxazolidine-3-carboxylic acid methyl ester (Compound Shown as Ic in Table 2: Exemplification Compound Number 7)

Following the procedure mentioned in Example 3, a similar reaction was carried out using (2R,4S)-2-isopropyl-4-hydroxymethyl-4-methyl-1,3-oxazolidine-3-carboxylic acid methyl ester (8.00 g, 36.8 mmol) synthesized according to the procedure described in Example 6 to afford the crude product of the title compound (7.13 g (determined by HPLC), yield: 90%). Additionally, it could be possible to obtain the pure title compound by purifying the crude product by chromatography on a silica gel column (eluent: a mixed solvent of ethyl acetate and hexane).

1 H NMR (CDCl 3 , 400 MHz): δ 0.85 (d, J=6.8 Hz, 3H), 0.93 (d, J=6.8 Hz, 3H), 1.46 (s, 3H), 2.20-2.54 (m, 1H), 3.63 (d, J=7.2 Hz, 1H), 3.72 (s, 3H), 4.07 (d, J=7.2 Hz, 1H), 4.98-5.25 (m, 1H), 9.60 (s, 1H). MS (FAB): m/z 216 (M+H + ), 186. HRMS (ESI): calcd for C 10 H 17 NNaO 4 (M+Na + ): 238.1055. found: 238.1032.

›Example 8

(2R,4R)-2-Isopropyl-4-methyl-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1,3-oxazolidine-3-carboxylic acid methyl ester (Compound Shown as Id in Table 3: Exemplification Compound Number 25)

Following the procedure mentioned in Example 4, a similar reaction was carried out using (2R,4S)-2-isopropyl-4-formyl-4-methyl-1,3-oxazolidine-3-carboxylic acid methyl ester (20.80 g, 96.6 mmol) synthesized according to the procedure described in Example 7 to afford the crude product of the title compound (25.33 g (determined by HPLC), yield: 89%). Additionally, it could be possible to obtain the pure title compound by purifying the crude product by chromatography on a silica gel column (eluent: a mixed solvent of ethyl acetate and hexane).

1 H NMR (DMSO-d 6 , 400 MHz): δ 0.83 (d, J=6.8 Hz, 3H), 0.91 (d, J=6.8 Hz, 3H), 1.35 (s, 3H), 1.80-2.15 (m, 3H), 2.44-2.52 (m, 2H), 3.47 (s, 3H), 3.53-3.72 (m, 4H), 3.95 (d, J=8.4 Hz, 1H), 4.90 (d, J=4.4 Hz, 1H), 5.70-5.73 (m, 1H), 5.83-5.85 (m, 1H), 6.57-6.60 (m, 1H). MS (FAB): m/z 295 (M+H + ), 148, 94. HRMS (FAB): calcd for C 16 H 26 N 2 O 3 : 294.1943. found: 294.1936.

›Example 9

(2R,4S)-2-Isopropyl-4-methyl-1,3-oxazolidine-3,4-dicarboxylic acid 3-t-butyl ester 4-methyl ester (Compound Shown as Ia in Table 1: Exemplification Compound Number 1)

(i) (2R,4S)-2-Isopropyl-1,3-oxazolidine-3,4-dicarboxylic acid 3-t-butyl ester 4-methyl ester

A mixture of (4S)-2-isopropyl-1,3-oxazolidine-4-carboxylic acid methyl ester (30.00 g, 173 mmol) synthesized according to the procedure described in Example 5 (i), Boc 2 O (39.8 mL, 173 mL) and tetrahydrofuran (300 mL) was stirred at about 45° C. for 4 hours. After stirring, the reaction mixture was cooled to about 25° C. and evaporated in vacuo to afford the crude product of the title compound (45.93 g (determined by HPLC), yield: 97%). Additionally, it could be possible to obtain the pure title compound by purifying the crude product by chromatography on a silica gel column (eluent: a mixed solvent of ethyl acetate and hexane).

1 H NMR (CDCl 3 , 400 MHz): δ 0.72 (d, J=6.8 Hz, 3H), 0.97 (d, J=6.8 Hz, 3H), 1.44 (s, 9H), 1.84-2.15 (m, 1H), 3.73 (s, 3H), 4.05-4.15 (m, 2H), 4.20-4.34 (m, 1H), 4.85-5.02 (m, 1H). MS (FAB): m/z 274 (M+H + ), 218, 174, 146, 130. HRMS (ESI): calcd for C 13 H 23 NNaO 5 (M+Na + ): 296.1474. found: 296.1492.

(ii) (2R,4S)-2-Isopropyl-4-methyl-1,3-oxazolidine-3,4-dicarboxylic acid 3-t-butyl ester 4-methyl ester

Following the procedure mentioned in Example 1, a similar reaction was carried out using (2R,4S)-2-isopropyl-1,3-oxazolidine-3,4-dicarboxylic acid 3-t-butyl ester 4-methyl ester (45.93 g, 168 mmol) synthesized according to the procedure described in Step (i) to afford the crude product of the title compound (41.27 g (determined by HPLC), yield: 86%). Additionally, it could be possible to obtain the pure title compound by purifying the crude product by chromatography on a silica gel column (eluent: a mixed solvent of ethyl acetate and hexane).

1 H NMR (CDCl 3 , 400 MHz): δ 0.85 (d, J=6.8 Hz, 3H), 0.95 (d, J=6.8 Hz, 3H), 1.41 (s, 9H), 1.57 (s, 3H), 2.20-2.53 (m, 1H), 3.73 (s, 3H), 3.75 (d, J=8.3 Hz, 1H), 4.14 (d, J=8.3 Hz, 1H), 4.85-5.16 (m, 1H). MS (FAB): m/z 288 (M+H + ), 232, 188, 144. HRMS (ESI): calcd for C 14 H 25 NNaO 5 (M+Na + ): 310.1630. found: 310.1604.

›Example 10

(2R,4S)-2-Isopropyl-4-hydroxymethyl-4-methyl-1,3-oxazolidine-3-carboxylic acid t-butyl ester (Compound Shown as Ib in Table 2: Exemplification Compound Number 1)

Following the procedure mentioned in Example 2, a similar reaction was carried out using (2R,4S)-2-isopropyl-4-methyl-1,3-oxazolidine-3,4-dicarboxylic acid 3-t-butyl ester 4-methyl ester (41.27 g, 144 mmol) synthesized according to the procedure described in Example 9 to afford the crude product of the title compound (35.23 g (determined by HPLC), yield: 95%). Additionally, it could be possible to obtain the pure title compound by purifying the crude product by chromatography on a silica gel column (eluent: a mixed solvent of ethyl acetate and hexane).

1 H NMR (CDCl 3 , 400 MHz): δ 0.84 (d, J=6.8 Hz, 3H), 0.93 (d, J=6.8 Hz, 3H), 1.40 (s, 3H), 1.44 (s, 9H), 2.00-2.15 (m, 1H), 3.38-3.82 (m, 4H), 4.90-4.98 (m, 1H). MS (FAB): m/z 260 (M+H + ), 204, 132. HRMS (ESI): calcd for C 13 H 25 NNaO 4 (M+Na + ): 282.1681. found: 282.1682.

›Example 11

(2R,4S)-2-Isopropyl-4-formyl-4-methyl-1,3-oxazolidine-3-carboxylic acid t-butyl ester (Compound Shown as Ic in Table 2: Exemplification Compound Number 1)

Following the procedure mentioned in Example 3, a similar reaction was carried out using (2R,4S)-2-isopropyl-4-hydroxymethyl-4-methyl-1,3-oxazolidine-3-carboxylic acid t-butyl ester (35.23 g, 136 mmol) synthesized according to the procedure described in Example 10 to afford the crude product of the title compound (24.80 g (determined by HPLC), yield: 71%). Additionally, it could be possible to obtain the pure title compound by purifying the crude product by chromatography on a silica gel column (eluent: a mixed solvent of ethyl acetate and hexane).

1 H NMR (CDCl 3 , 400 MHz): δ 0.89 (d, J=6.8 Hz, 3H), 0.98 (d, J=6.8 Hz, 3H), 1.42 (s, 9H), 1.45 (s, 3H), 2.10-2.55 (m, 1H), 3.61 (d, J=8.2 Hz, 1H), 4.04 (d, J=8.2 Hz, 1H), 4.85-5.18 (m, 1H), 9.55 (s, 1H). MS (FAB): m/z 258 (M+H + ), 202, 130. HRMS (FAB): calcd for C 13 H 24 NO 4 (M+H + ): 258.1705. found: 258.1709.

›Example 12

(2R,4R)-2-Isopropyl-4-methyl-4-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1,3-oxazolidine-3-carboxylic acid t-butyl ester (Compound Shown as Id in Table 3: Exemplification Compound Number 1)

Following the procedure mentioned in Example 4, a similar reaction was carried out using (2R,4S)-2-isopropyl-4-formyl-4-methyl-1,3-oxazolidine-3-carboxylic acid t-butyl ester (8.00 g, 31.1 mmol) synthesized according to the procedure described in Example 11 to afford the crude product of the title compound (10.17 g (determined by HPLC), yield: 97%). Additionally, it could be possible to obtain the pure title compound by purifying the crude product by chromatography on a silica gel column (eluent: a mixed solvent of ethyl acetate and hexane).

1 H NMR: (DMSO-d 6 , 400 MHz): δ 0.83 (d, J=6.8 Hz, 3H), 0.93 (d, J=6.8 Hz, 3H), 1.35 (s, 3H), 1.41 (s, 9H), 1.80-2.15 (m, 3H), 2.43-2.53 (m, 2H), 3.37 (s, 3H), 3.58 (d, J=7.6 Hz, 1H), 3.94 (d, J=7.6 Hz, 1H), 4.85 (d, J=4.4 Hz, 1H), 5.71-5.74 (m, 1H), 5.82-5.86 (m, 1H), 6.57-6.60 (m, 1H). MS (FAB): m/z 336 (M + ), 281, 148, 94. HRMS (ESI): calcd for C 19 H 32 N 2 NaO 3 (M+Na + ): 359.2311. found: 359.2292.

›Example 13

(2R,4S)-2-(2-Ethylpropyl)-4-methyl-1,3-oxazolidine-3,4-dicarboxylic acid dimethyl ester (Compound Shown as Ia in Table 1: Exemplification Compound Number 97)

(i) (4S)-2-(2-Ethylpropyl)-1,3-oxazolidine-4-carboxylic acid methyl ester

To a suspension of L-serine methyl ester hydrochloride (50.00 g, 321 mmol) in toluene (500 mL) were added successively 2-methylpropanal (47.5 mL, 386 mmol), triethylamine (49.3 mL, 354 mmol) and water-absorbing polymer (2.50 g) under a nitrogen atmosphere with stirring, and the resulting mixture was stirred at 45° C. for 2 hours under the nitrogen atmosphere. After cooling the reaction mixture to 25° C., the insoluble materials were filtered off, and the insoluble materials were washed with toluene (250 mL). The filtrate and the washings were combined and evaporated in vacuo to afford the crude product of the title compound (55.83 g, yield: 86%).

1 H NMR (CDCl 3 , 400 MHz): δ 0.83-0.93 (m, 9H), 1.28-1.59 (m, 4H), 2.45-2.55 (m, 1H), 3.66-3.98 (m, 3H), 4.02-4.46 (m, 2H). MS (FAB): m/z 202 (M+H + ), 200, 130. HRMS (ESI): calcd for C 10 H 19 NNaO 3 (M+Na + ): 224.1263. found: 224.1262.

(ii) (2R,4S)-2-(2-Ethylpropyl)-1,3-oxazolidine-3,4-dicarboxylic acid dimethyl ester

Following the procedure mentioned in Example 5 (ii), a similar reaction was carried out using (4S)-2-(2-ethylpropyl)-1,3-oxazolidine-4-carboxylic acid methyl ester (5.00 g, 24.8 mmol) synthesized according to the procedure described in Step (i) to afford the crude product of the title compound. The crude product thus obtained was purified by chromatography on a silica gel column (eluent: a mixed solvent of ethyl acetate and hexane) to afford the pure title compound (5.21 g, yield: 81%).

1 H NMR (CDCl 3 , 400 MHz): δ 0.70 (t, J=7.6 Hz, 3H), 0.86 (t, J=7.6 Hz, 3H), 1.15-1.95 (m, 5H), 3.71 (s, 3H), 3.74 (s, 3H), 4.04-4.19 (m, 2H), 4.40-4.64 (m, 1H), 5.05-5.18 (m, 1H). MS (FAB): m/z 260 (M+H + ), 188, 160. HRMS (ESI): calcd for C 12 H 21 NNaO 5 (M+Na + ): 282.1317. found: 282.1327.

(iii) (2R,4S)-2-(2-Ethylpropyl)-4-methyl-1,3-oxazolidine-3,4-dicarboxylic acid dimethyl ester

Following the procedure mentioned in Example 1, a similar reaction was carried out using (2R,4S)-2-(2-ethylpropyl)-1,3-oxazolidine-3,4-dicarboxylic acid dimethyl ester (5.21 g, 20.1 mmol) synthesized according to the procedure described in Step (ii) to afford the crude product of the title compound. The crude product thus obtained was purified by the reverse phase chromatography (eluent: a mixed solvent of acetonitrile and water) to afford the pure title compound (5.09 g, yield: 93%).

1 H NMR (CDCl 3 , 400 MHz): δ 0.89 (t, J=7.6 Hz, 3H), 0.95 (t, J=7.6 Hz, 3H), 1.15-1.70 (m, 7H), 1.78-2.13 (m, 1H), 3.69 (s, 3H), 3.73-3.78 (m, 4H), 4.20 (d, J=8.5 Hz, 1H), 5.18-5.29 (m, 1H). MS (FAB): m/z 274 (M+H + ), 202, 174. HRMS (ESI): calcd for C 13 H 23 NNaO 5 (M+Na + ): 296.1474. found: 296.1489.

›Example 14

(2R,4S)-2-(2-Ethylpropyl)-4-hydroxymethyl-4-methyl-1,3-oxazolidine-3-carboxylic acid methyl ester (Compound Shown as Ib in Table 2: Exemplification Compound Number 49)

Following the procedure mentioned in Example 2, a similar reaction was carried out using (2R,4S)-2-(2-ethylpropyl)-4-methyl-1,3-oxazolidine-3,4-dicarboxylic acid dimethyl ester (5.09 g, 18.6 mmol) synthesized according to the procedure described in Example 13 to afford the crude product of the title compound. The crude product thus obtained was purified by the reverse phase chromatography (eluent: a mixed solvent of acetonitrile and water) to afford the pure title compound (3.35 g, yield: 73%).

1 H NMR (CDCl 3 , 400 MHz): δ 0.70 (t, J=7.6 Hz, 3H), 0.84 (t, J=7.6 Hz, 3H), 1.12-1.70 (m, 7H), 1.90-2.25 (m, 1H), 3.40-3.82 (m, 7H), 5.20 (d, J=4.0 Hz, 1H). MS (FAB): m/z 246 (M+H + ), 174, 146. HRMS (ESI): calcd for C 12 H 23 NNaO 4 (M+Na + ): 268.1525. found: 268.1539.

›Example 15

(2R,4S)-2-(2-Ethylpropyl)-4-formyl-4-methyl-1,3-oxazolidine-3-carboxylic acid methyl ester (Compound Shown as Ic in Table 2: Exemplification Compound Number 49)

Following the procedure mentioned in Example 3, a similar reaction was carried out using (2R,4S)-2-(2-ethylpropyl)-4-hydroxymethyl-4-methyl-1,3-oxazolidine-3-carboxylic acid methyl ester (3.00 g, 12.2 mmol) synthesized according to the procedure described in Example 14 to afford the crude product of the title compound. The crude product thus obtained Was purified by chromatography on a silica gel column (eluent: a mixed solvent of ethyl acetate and hexane) to afford the pure title compound (2.55 g, yield: 86%).

1 H NMR (CDCl 3 , 400 MHz): δ 0.73 (t, J=7.6 Hz, 3H), 0.80 (t, J=7.6 Hz, 3H), 1.12-1.56 (m, 7H), 1.85-2.12 (m, 1H), 3.62 (d, J=8.8 Hz, 1H), 3.71 (s, 3H), 4.10 (d, J=8.8 Hz, 1H), 5.15-5.34 (m, 1H), 9.63 (s, 1H). MS (FAB): m/z 244 (M+H + ), 144. HRMS (ESI): calcd for C 12 H 23 NNaO 4 (M+Na + ): 266.1368. found: 266.1378.

›Example 16

(2R,4R)-2-(2-Ethylpropyl)-4-methyl-4-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1,3-oxazolidine-3-carboxylic acid methyl ester (Compound Shown as Id in Table 3: Exemplification Compound Number 265)

Following the procedure mentioned in Example 4, a similar reaction was carried out using (2R,4S)-2-(2-ethylpropyl)-4-formyl-4-methyl-1,3-oxazolidine-3-carboxylic acid methyl ester (2.00 g, 8.2 mmol) synthesized according to the procedure described in Example 15 to afford the crude product of the title compound. The crude product thus obtained was purified by reverse phase chromatography (eluent: a mixed solvent of acetonitrile and water) to afford the pure title compound (2.04 g, yield: 77%).

1 H NMR (DMSO-d 6 , 400 MHz): δ 0.85 (d, J=7.6 Hz, 3H), 0.91 (d, J=7.6 Hz, 3H), 1.15-1.50 (m, 7H), 1.85-2.14 (m, 3H), 2.44-2.54 (m, 2H), 3.48 (s, 3H), 3.56-3.61 (m, 4H), 3.94 (d, J=8.8 Hz, 1H), 5.09 (d, J=4.4 Hz, 1H), 5.69-5.73 (m, 1H), 5.83-5.86 (m, 1H), 6.56-6.60 (m, 1H). MS (FAB): m/z 323 (M+H + ), 148. HRMS (ESI): calcd for C 18 H 31 N 2 O 3 (M+H + ): 323.2335. found: 323.2349.

›Example 17

(2R,4S)-2-(2-Ethylpropyl)-4-hydroxymethyl-4-methyl-1,3-oxazolidine-3-carboxylic acid t-butyl ester (Compound Shown as Ia in Table 1: Exemplification Compound Number 85)

(i) (2R,4S)-2-(2-Ethylpropyl)-1,3-oxazolidine-3,4-dicarboxylic acid 3-t-butyl ester 4-methyl ester

Following the procedure mentioned in Example 9 (i), a similar reaction was carried out using (4S)-2-(2-ethylpropyl)-1,3-oxazolidine-4-carboxylic acid methyl ester (5.00 g, 24.8 mmol) synthesized according to the procedure described in Example 13(i) to afford the crude product of the title compound. The crude product thus obtained was purified by chromatography on a silica gel column (eluent: a mixed solvent of ethyl acetate and hexane) to afford the pure title compound (6.52 g, yield: 87%).

1 H NMR (CDCl 3 , 400 MHz): δ 0.69 (t, J=7.6 Hz, 3H), 0.75 (t, J=7.6 Hz, 3H), 1.15-1.95 (m, 14H), 3.74 (s, 3H), 4.04-4.10 (m, 2H), 4.34-4.68 (m, 1H), 5.01-5.20 (m, 1H). MS (FAB): m/z 302 (M+H + ), 246, 146. HRMS (ESI): calcd for C 15 H 27 NNaO 5 (M+Na + ): 324.1787. found: 324.1801.

(ii) (2R,4S)-2-(2-Ethylpropyl)-4-methyl-1,3-oxazolidine-3,4-dicarboxylic acid 3-t-butyl ester 4-methyl ester

Following the procedure mentioned in Example 1, a similar reaction was carried out using (2R,4S)-2-(2-ethylpropyl)-1,3-oxazolidine-3,4-dicarboxylic acid 3-t-butyl ester 4-methyl ester (4.00 g, 13.3 mmol) synthesized according to the procedure described in Step (i) to afford the crude product of the title compound. The crude product thus obtained was purified by chromatography on a silica gel column (eluent: a mixed solvent of ethyl acetate and hexane) to afford the pure title compound (3.35 g, yield: 80%).

1 H NMR (CDCl 3 , 400 MHz): δ 0.75 (t, J=7.6 Hz, 3H), 0.86 (t, J=7.6 Hz, 3H), 1.02-2.02 (m, 17H), 3.59-3.63 (m, 4H), 4.14 (d, J=8.3 Hz, 1H), 5.13-5.27 (m, 1H). MS (FAB): m/z 316 (M+H + ), 216, 214. HRMS (ESI): calcd for C 16 H 29 NNaO 5 (M+Na + ): 338.1943. found: 338.1960.

›Example 18

(2R,4S)-2-(2-Ethylpropyl)-4-hydroxymethyl-4-methyl-1,3-oxazolidine-3-carboxylic acid t-butyl ester (Compound Shown as Ib in Table 2: Exemplification Compound Number 43)

Following the procedure mentioned in Example 2, a similar reaction was carried out using (2R,4S)-2-(2-ethylpropyl)-4-methyl-1,3-oxazolidine-3,4-dicarboxylic acid 3-t-butyl ester 4-methyl ester (2.50 g, 8.0 mmol) synthesized according to the procedure described in Example 17 to afford the crude product of the title compound. The crude product thus obtained was purified by reverse phase chromatography (eluent: a mixed solvent of acetonitrile and water) to afford the pure title compound (2.17 g, yield: 95%

1 H NMR (CDCl 3 , 400 MHz): δ 0.89 (t, J=7.6 Hz, 3H), 0.95 (t, J=7.6 Hz, 3H), 1.14-2.04 (m, 17H), 3.50-3.79 (m, 4H), 5.18 (d, J=3.3 Hz, 1H). MS (FAB): m/z 288 (M+H + ), 232, 132. HRMS (ESI): calcd for C 15 H 29 NNaO 4 (M+Na + ): 310.1994. found: 310.1992.

›Example 19

(2R,4S)-2-(2-Ethylpropyl)-4-formyl-4-methyl-1,3-oxazolidine-3-carboxylic acid t-butyl ester (Compound Shown as Ic in Table 2: Exemplification Compound Number 43)

Following the procedure mentioned in Example 3, a similar reaction was carried out using (2R,4S)-2-(2-ethylpropyl)-4-hydroxymethyl-4-methyl-1,3-oxazolidine-3-carboxylic acid t-butyl ester (1.50 g, 5.2 mmol) synthesized according to the procedure described in Example 18 to afford the crude product of the title compound. The crude product thus obtained was purified by chromatography on a silica gel column (eluent: a mixed solvent of ethyl acetate and hexane) to afford the pure title compound (1.30 g, yield: 87%).

1 H NMR (CDCl 3 , 400 MHz): δ 0.75 (t, J=7.6 Hz, 3H), 0.84 (t, J=7.6 Hz, 3H), 1.03-2.13 (m, 17H), 3.59 (d, J=9.0 Hz, 1H), 4.02 (d, J=9.0 Hz, 1H), 5.12-5.33 (m, 1H), 9.60 (s, 1H). MS (FAB): m/z 286 (M+H + ), 230, 130. HRMS (ESI): calcd for C 15 H 27 NNaO 4 (M+Na + ): 308.1838. found: 308.1853.

›Example 20

(2R,4R)-2-(2-Ethylpropyl)-4-methyl-4-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]-1,3-oxazolidine-3-carboxylic acid t-butyl ester (Compound Shown as Id in Table 3: Exemplification Compound Number 241)

Following the procedure mentioned in Example 4, a similar reaction was carried out using (2R,4S)-2-(2-ethylpropyl)-4-formyl-4-methyl-1,3-oxazolidine-3-carboxylic acid t-butyl ester (1.00 g, 3.5 mmol) synthesized according to the procedure described in Example 19 to afford the crude product of the title compound. The crude product thus obtained was purified by reverse phase chromatography (eluent: a mixed solvent of acetonitrile and water) to afford the pure title compound (1.01 g, yield: 79%).

1 H NMR (DMSO-d 6 , 400 MHz): δ 0.83 (d, J=7.6 Hz, 3H), 0.91 (d, J=7.6 Hz, 3H), 1.10-1.48 (m, 16H), 1.80-2.03 (m, 3H), 2.45-2.53 (m, 2H), 3.48 (s, 3H), 3.56 (d, J=8.6 Hz, 1H), 3.92 (d, J=8.6 Hz, 1H), 5.04 (d, J=4.0 Hz, 1H), 5.68-5.72 (m, 1H), 5.83-5.86 (m, 1H), 6.56-6.60 (m, 1H). MS (FAB): m/z 365 (M+H + ), 309, 148, 94. HRMS (ESI): calcd for C 21 H 37 N 2 O 3 (M+H + ): 365.2804. found: 365.281.

›Example 21

[(1-Methyl-1H-pyrrol-2-yl)methyl] (triphenyl)phosphonium chloride

To a suspension of triphenylphosphine (3.83 g, 14.6 mmol) in acetonitrile (17 mL) was added acetyl chloride (1.04 mL, 14.6 mmol) under ice-cooling with stirring. Subsequently, to the resulting mixture was added dropwise slowly a solution of 1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-pyrrole (2.00 g, 12.2 mmol) synthesized by the procedure described in the literature (J. Am. Chem. Soc. 73, 4921 (1951)) in toluene (17 mL) below 5° C. with stirring, and the resulting mixture was stirred under ice-cooling for 2 hours. After stirring, the precipitate formed was collected by filtration to afford the almost pure title compound (4.74 g, yield: 99%).

1 H NMR (DMSO-d 6 , 400 MHz): δ 2.96 (s, 3H), 5.27 (d, 2H, J PH =13.5 Hz), 5.59 (d, 1H, J=1.7 Hz), 5.91 (dd, 1H, J=1.7, 1.7 Hz), 6.69 (d, 1H, J=1.7 Hz), 7.60-8.00 (m, 15H). 13 C NMR (DMSO-d 6 , 100 MHz): δ 20.5, 21.0, 33.1, 107.6, 107.6, 110.8, 110.9, 116.7, 116.8, 117.6, 118.5, 123.8, 123.8, 130.0, 130.1, 133.8, 133.9, 135.1, 135.1. IR νmax (KBr): 3116, 3098, 3077, 3054, 3001, 2992, 2866, 2837, 2765, 1486, 1437, 1306, 1143, 1108, 998, 745, 736, 716, 692, 520, 505, 486 cm −1 .

Additionally, following the procedure mentioned above, a similar reaction was carried out using 1-methyl-2-(N,N-dimethylaminomethyl)-1H-pyrrole, 1-methyl-2-(N,N-diethylaminomethyl)-1H-pyrrole and 1-methyl-2-(piperidin-1-ylmethyl)-1H-pyrrole as the starting materials instead of 1-methyl-2-(pyrrolidin-1-ylmethyl)-1H-pyrrole, and propionyl chloride or isobutyloyl chloride as the reagent instead of acetyl chloride to afford the title compound in the same yield.

›Example 22

(4-Methoxybenzyl)(triphenyl)phosphonium iodide

To a suspension of triphenylphosphine (4.92 g, 18.8 mmol) in acetonitrile (10 mL) was added acetyl chloride (1.34 mL, 18.8 mmol) at room temperature with stirring, and the resulting mixture was warmed to about 50° C. Subsequently, to the reaction mixture was added dropwise slowly a solution of 1-(4-methoxybenzyl)pyrrolidine (1.00 g, 5.23 mmol) in toluene (10 mL) below 60° C. with stirring, and the resulting mixture was stirred at about 50° C. for 72 hours. After cooling the reaction mixture to room temperature, water (20 mL) and n-hexane (10 mL) were added to the reaction mixture, and the resulting mixture was partitioned. To the aqueous layer separated were added successively water (10 mL) and sodium iodide (0.94 g, 6.28 mmol) with stirring, and the resulting mixture was stirred under ice-cooling for 1 hour. After stirring, the precipitate formed was collected by filtration to afford the almost pure title compound (2.31 g, yield: 87%).

1 H NMR (DMSO-d 6 , 400 MHz): δ 3.70 (s, 3H), 5.14 (d, 2H, J PH =32.0 Hz), 6.70-7.00 (m, 4H), 7.60-8.00 (m, 15H). 13 C NMR (DMSO-d 6 , 100 MHz): δ 27.2, 27.7, 55.1, 114.2, 114.2, 117.4, 118.3, 119.0, 119.0, 130.0, 130.1, 131.9, 132.0, 133.9, 134.0, 135.0, 135.0, 159.1, 159.1. IR νmax (KBr): 3036, 3005, 2962, 2882, 2854, 2787, 1610, 1584, 1512, 1439, 1254, 1178, 1112, 1030, 836, 740, 719, 688, 510 cm −1 .

›Example 23

Triphenyl(thien-2-ylmethyl)phosphonium iodide

To a suspension of triphenylphosphine (6.66 g, 25.5 mmol) in acetonitrile (10 mL) was added acetyl chloride (1.80 mL, 25.5 mmol) at room temperature with stirring, and the resulting mixture was warmed to about 50° C. Subsequently, to the reaction mixture was added dropwise slowly a solution of 2-(dimethylaminomethyl)thiophene (1.00 g, 7.08 mmol) in toluene (10 mL) below 60° C. with stirring, and the resulting mixture was stirred at about 50° C. for 75 hours. After cooling the reaction mixture to room temperature, water (20 mL) and n-hexane (10 mL) were added to the reaction mixture, and the resulting mixture was partitioned. To the aqueous layer separated were added successively water (10 mL) and sodium iodide (1.27 g, 8.50 mmol) with stirring, and the resulting mixture was stirred under ice-cooling for 1 hour. After stirring, the precipitate formed was collected by filtration to afford the almost pure title compound (2.94 g, yield: 85%).

1 H NMR (DMSO-d 6 , 400 MHz): δ 5.51 (d, 2H, J PH =14.6 Hz), 6.70-6.80 (m, 1H), 6.90-7.00 (m, 1H), 7.40-7.50 (m, 1H), 7.60-8.00 (m, 15H). 13 C NMR (DMSO-d 6 , 100 MHz): δ 23.7, 24.2, 117.3, 118.1, 127.3, 127.4, 127.9, 127.9, 128.3, 128.4, 130.1, 130.2, 130.4, 130.5, 133.9, 134.0, 135.2, 135.2. IR νmax (KBr): 3065, 3046, 3004, 2986, 2867, 2829, 1585, 1484, 1435, 1161, 1109, 995, 860, 754, 742, 720, 690, 516, 498 cm −1 .

›Example 24

[(5-Methyl-2-furyl)methyl](triphenyl)phosphonium iodide

To a suspension of triphenylphosphine (6.79 g, 25.9 mmol) in acetonitrile (10 mL) was added acetyl chloride (1.84 mL, 25.9 mmol) at room temperature with stirring, and the resulting mixture was warmed to about 50° C. Subsequently, to the reaction mixture was added dropwise slowly a solution of N,N,5-trimethylfurfurylamine (1.00 g, 7.18 mmol) in toluene (10 mL) below 60° C. with stirring, and the resulting mixture was stirred at about 50° C. for 72 hours. After cooling the reaction mixture to room temperature, water (20 mL) and n-hexane (10 mL) were added to the reaction mixture, and the resulting mixture was partitioned. To the aqueous layer separated were added successively water (10 mL) and sodium iodide (1.29 g, 8.61 mmol) with stirring, and the resulting mixture was stirred under ice-cooling for 1 hour. After stirring, the precipitate formed was collected by filtration to afford the almost pure title compound (3.20 g, yield: 92%).

1 H NMR (DMSO-d 6 , 400 MHz): δ 2.04 (s, 3H), 5.32 (d, 2H, J PH =14.5 Hz), 5.95-6.05 (m, 2H), 7.60-8.00 (m, 15H). 13 C NMR (DMSO-d 6 , 100 MHz): δ 13.0, 22.7, 23.2, 107.3, 107.3, 112.8, 112.9, 117.5, 118.4, 130.0, 130.1, 133.8, 133.9, 135.1, 135.1, 139.5, 139.6, 152.6, 152.7. IR νmax (KBr): 3050, 3007, 2988, 2871, 2832, 2770, 1715, 1611, 1586, 1561, 1484, 1437, 1143, 1111, 1023, 996, 943, 799, 745, 732, 689, 522, 504, 485 cm −1 .

›POSSIBILITY OF INDUSTRIAL USE

The present invention is useful for providing optically active 4,4-di-substituted oxazolidine derivatives and procedures for their preparation. The preparation procedures of the present invention have excellent advantages in the following respects, compared with the prior art: 1) increase in yield, 2) improvement in stereoselectivity, 3) extremely low-temperature reaction which is unsuitable for industrial large-scale synthesis is not necessary, and 4) column-chromatographic purification of intermediates is not needed in any step of these synthetic processes.

Furthermore, the compounds having the general formula (Id), which are optically active 4,4-di-substituted oxazolidine derivatives encompassed in the present invention, are useful as the synthetic intermediates in the preparation of optically active α,α-di-substituted α-amino acid derivatives having an excellent glutamate receptor antagonistic action or optically active α,α-di-substituted amino alcohol derivatives having new immunosuppressive action.

Additionally, according to the present invention, the substituted methylenephosphonium salt which is useful as a synthetic intermediate in the preparation of compounds having the general formula (Id) and various kinds of medicines can be obtained conveniently in a high yield.

›Tables in the description — 3

TABLE 1 — (Ia) Compound

No.	R 2	R 3	R 4	R
1	iPr	Boc	Me	Me
2	iPr	Boc	Me	Et
3	iPr	Boc	Et	Me
4	iPr	Boc	Et	Et
5	iPr	Boc	Pr	Me
6	iPr	Boc	Pr	Et
7	iPr	Cbz	Me	Me
8	iPr	Cbz	Me	Et
9	iPr	Cbz	Et	Me
10	iPr	Cbz	Et	Et
11	iPr	Cbz	Pr	Me
12	iPr	Cbz	Pr	Et
13	iPr	Moc	Me	Me
14	iPr	Moc	Me	Et
15	iPr	Moc	Et	Me
16	iPr	Moc	Et	Et
17	iPr	Moc	Pr	Me
18	iPr	Moc	Pr	Et
19	iPr	Eoc	Me	Me
20	iPr	Eoc	Me	Et
21	iPr	Eoc	Et	Me
22	iPr	Eoc	Et	Et
23	iPr	Eoc	Pr	Me
24	iPr	Eoc	Pr	Et
25	iPr	Ac	Me	Me
26	iPr	Ac	Me	Et
27	iPr	Ac	Et	Me
28	iPr	Ac	Et	Et
29	iPr	Ac	Pr	Me
30	iPr	Ac	Pr	Et
31	iPr	PhOCO	Me	Me
32	iPr	PhOCO	Me	Et
33	iPr	PhOCO	Et	Me
34	iPr	PhOCO	Et	Et
35	iPr	PhOCO	Pr	Me
36	iPr	PhOCO	Pr	Et
37	iPr	Bzl	Me	Me
38	iPr	Bzl	Me	Et
39	iPr	Bzl	Et	Me
40	iPr	Bzl	Et	Et
41	iPr	Bzl	Pr	Me
42	iPr	Bzl	Pr	Et
43	tBu	Boc	Me	Me
44	tBu	Boc	Me	Et
45	tBu	Boc	Et	Me
46	tBu	Boc	Et	Et
47	tBu	Boc	Pr	Me
48	tBu	Boc	Pr	Et
49	tBu	Cbz	Me	Me
50	tBu	Cbz	Me	Et
51	tBu	Cbz	Et	Me
52	tBu	Cbz	Et	Et
53	tBu	Cbz	Pr	Me
54	tBu	Cbz	Pr	Et
55	tBu	Moc	Me	Me
56	tBu	Moc	Me	Et
57	tBu	Moc	Et	Me
58	tBu	Moc	Et	Et
59	tBu	Moc	Pr	Me
60	tBu	Moc	Pr	Et
61	tBu	Eoc	Me	Me
62	tBu	Eoc	Me	Et
63	tBu	Eoc	Et	Me
64	tBu	Eoc	Et	Et
65	tBu	Eoc	Pr	Me
66	tBu	Eoc	Pr	Et
67	tBu	Ac	Me	Me
68	tBu	Ac	Me	Et
69	tBu	Ac	Et	Me
70	tBu	Ac	Et	Et
71	tBu	Ac	Pr	Me
72	tBu	Ac	Pr	Et
73	tBu	PhOCO	Me	Me
74	tBu	PhOCO	Me	Et
75	tBu	PhOCO	Et	Me
76	tBu	PhOCO	Et	Et
77	tBu	PhOCO	Pr	Me
78	tBu	PhOCO	Pr	Et
79	tBu	Bzl	Me	Me
80	tBu	Bzl	Me	Et
81	tBu	Bzl	Et	Me
82	tBu	Bzl	Et	Et
83	tBu	Bzl	Pr	Me
84	tBu	Bzl	Pr	Et
85	Et 2 CH	Boc	Me	Me
86	Et 2 CH	Boc	Me	Et
87	Et 2 CH	Boc	Et	Me
88	Et 2 CH	Boc	Et	Et
89	Et 2 CH	Boc	Pr	Me
90	Et 2 CH	Boc	Pr	Et
91	Et 2 CH	Cbz	Me	Me
92	Et 2 CH	Cbz	Me	Et
93	Et 2 CH	Cbz	Et	Me
94	Et 2 CH	Cbz	Et	Et
95	Et 2 CH	Cbz	Pr	Me
96	Et 2 CH	Cbz	Pr	Et
97	Et 2 CH	Moc	Me	Me
98	Et 2 CH	Moc	Me	Et
99	Et 2 CH	Moc	Et	Me
100	Et 2 CH	Moc	Et	Et
101	Et 2 CH	Moo	Pr	Me
102	Et 2 CH	Moc	Pr	Et
103	Et 2 CH	Eoc	Me	Me
104	Et 2 CH	Eoc	Me	Et
105	Et 2 CH	Eoc	Et	Me
106	Et 2 CH	Eoc	Et	Et
107	Et 2 CH	Eoc	Pr	Me
108	Et 2 CH	Eoc	Pr	Et
109	Et 2 CH	Ac	Me	Me
110	Et 2 CH	Ac	Me	Et
111	Et 2 CH	Ac	Et	Me
112	Et 2 CH	Ac	Et	Et
113	Et 2 CH	Ac	Pr	Me
114	Et 2 CH	Ac	Pr	Et
115	Et 2 CH	PhOCO	Me	Me
116	Et 2 CH	PhOCO	Me	Et
117	Et 2 CH	PhOCO	Et	Me
118	Et 2 CH	PhOCO	Et	Et
119	Et 2 CH	PhOCO	Pr	Me
120	Et 2 CH	PhOCO	Pr	Et
121	Et 2 CH	Bzl	Me	Me
122	Et 2 CH	Bzl	Me	Et
123	Et 2 CH	Bzl	Et	Me
124	Et 2 CH	Bzl	Et	Et
125	Et 2 CH	Bzl	Pr	Me
126	Et 2 CH	Bzl	Pr	Et
127	Ph	Boc	Me	Me
128	Ph	Boc	Me	Et
129	Ph	Boc	Et	Me
130	Ph	Boc	Et	Et
131	Ph	Boc	Pr	Me
132	Ph	Boc	Pr	Et
133	Ph	Cbz	Me	Me
134	Ph	Cbz	Me	Et
135	Ph	Cbz	Et	Me
136	Ph	Cbz	Et	Et
137	Ph	Cbz	Pr	Me
138	Ph	Cbz	Pr	Et
139	Ph	Moc	Me	Me
140	Ph	Moc	Me	Et
141	Ph	Moc	Et	Me
142	Ph	Moc	Et	Et
143	Ph	Moc	Pr	Me
144	Ph	Moc	Pr	Et
145	Ph	Eoc	Me	Me
146	Ph	Eoc	Me	Et
147	Ph	Eoc	Et	Me
148	Ph	Eoc	Et	Et
149	Ph	Eoc	Pr	Me
150	Ph	Eoc	Pr	Et
151	Ph	Ac	Me	Me
152	Ph	Ac	Me	Et
153	Ph	Ac	Et	Me
154	Ph	Ac	Et	Et
155	Ph	Ac	Pr	Me
156	Ph	Ac	Pr	Et
157	Ph	PhOCO	Me	Me
158	Ph	PhOCO	Me	Et
159	Ph	PhOCO	Et	Me
160	Ph	PhOCO	Et	Et
161	Ph	PhOCO	Pr	Me
162	Ph	PhOCO	Pr	Et
163	Ph	Bzl	Me	Me
164	Ph	Bzl	Me	Et
165	Ph	Bzl	Et	Me
166	Ph	Bzl	Et	Et
167	Ph	Bzl	Pr	Me
168	Ph	Bzl	Pr	Et
169	cHex	Boc	Me	Me
170	cHex	Boc	Me	Et
171	cHex	Boc	Et	Me
172	cHex	Boc	Et	Et
173	cHex	Boc	Pr	Me
174	cHex	Boc	Pr	Et
175	cHex	Cbz	Me	Me
176	cHex	Cbz	Me	Et
177	cHex	Cbz	Et	Me
178	cHex	Cbz	Et	Et
179	cHex	Cbz	Pr	Me
180	cHex	Cbz	Pr	Et
181	cHex	Moc	Me	Me
182	cHex	Moc	Me	Et
183	cHex	Moc	Et	Me
184	cHex	Moc	Et	Et
185	cHex	Moc	Pr	Me
186	cHex	Moc	Pr	Et
187	cHex	Eoc	Me	Me
188	cHex	Eoc	Me	Et
189	cHex	Eoc	Et	Me
190	cHex	Eoc	Et	Et
191	cHex	Eoc	Pr	Me
192	cHex	Eoc	Pr	Et
193	cHex	Ac	Me	Me
194	cHex	Ac	Me	Et
195	cHex	Ac	Et	Me
196	cHex	Ac	Et	Et
197	cHex	Ac	Pr	Me
198	cHex	Ac	Pr	Et
199	cHex	PhOCO	Me	Me
200	cHex	PhOCO	Me	Et
201	cHex	PhOCO	Et	Me
202	cHex	PhOCO	Et	Et
203	cHex	PhOCO	Pr	Me
204	cHex	PhOCO	Pr	Et
205	cHex	Bzl	Me	Me
206	cHex	Bzl	Me	Et
207	cHex	Bzl	Et	Me
208	cHex	Bzl	Et	Et
209	cHex	Bzl	Pr	Me
210	cHex	Bzl	Pr	Et

TABLE 2 — Compound

No.	R 2	R 3	R 4
1	iPr	Boc	Me
2	iPr	Boc	Et
3	iPr	Boc	Pr
4	iPr	Cbz	Me
5	iPr	Cbz	Et
6	iPr	Cbz	Pr
7	iPr	Moc	Me
8	iPr	Moc	Et
9	iPr	Moc	Pr
10	iPr	Eoc	Me
11	iPr	Eoc	Et
12	iPr	Eoc	Pr
13	iPr	Ac	Me
14	iPr	Ac	Et
15	iPr	Ac	Pr
16	iPr	PhOCO	Me
17	iPr	PhOCO	Et
18	iPr	PhOCO	Pr
19	iPr	Bzl	Me
20	iPr	Bzl	Et
21	iPr	Bzl	Pr
22	tBu	Boc	Me
23	tBu	Boc	Et
24	tBu	Boc	Pr
25	tBu	Cbz	Me
26	tBu	Cbz	Et
27	tBu	Cbz	Pr
28	tBu	Moc	Me
29	tBu	Moc	Et
30	tBu	Moc	Pr
31	tBu	Eoc	Me
32	tBu	Eoc	Et
33	tBu	Eoc	Pr
34	tBu	Ac	Me
35	tBu	Ac	Et
36	tBu	Ac	Pr
37	tBu	PhOCO	Me
38	tBu	PhOCO	Et
39	tBu	PhOCO	Pr
40	tBu	Bzl	Me
41	tBu	Bzl	Et
42	tBu	Bzl	Pr
43	Et 2 CH	Boc	Me
44	Et 2 CH	Boc	Et
45	Et 2 CH	Boc	Pr
46	Et 2 CH	Cbz	Me
47	Et 2 CH	Cbz	Et
48	Et 2 CH	Cbz	Pr
49	Et 2 CH	Moc	Me
50	Et 2 CH	Moc	Et
51	Et 2 CH	Moc	Pr
52	Et 2 CH	Eoc	Me
53	Et 2 CH	Eoc	Et
54	Et 2 CH	Eoc	Pr
55	Et 2 CH	Ac	Me
56	Et 2 CH	Ac	Et
57	Et 2 CH	Ac	Pr
58	Et 2 CH	PhOCO	Me
59	Et 2 CH	PhOCO	Et
60	Et 2 CH	PhOCO	Pr
61	Et 2 CH	Bzl	Me
62	Et 2 CH	Bzl	Et
63	Et 2 CH	Bzl	Pr
64	Ph	Boc	Me
65	Ph	Boc	Et
66	Ph	Boc	Pr
67	Ph	Cbz	Me
68	Ph	Cbz	Et
69	Ph	Cbz	Pr
70	Ph	Moc	Me
71	Ph	Moc	Et
72	Ph	Moc	Pr
73	Ph	Boc	Me
74	Ph	Boc	Et
75	Ph	Boc	Pr
76	Ph	Ac	Me
77	Ph	Ac	Et
78	Ph	Ac	Pr
79	Ph	PhOCO	Me
80	Ph	PhOCO	Et
81	Ph	PhOCO	Pr
82	Ph	Bzl	Me
83	Ph	Bzl	Et
84	Ph	Bzl	Pr
85	cHex	Boc	Me
86	cHex	Boc	Et
87	cHex	Boc	Pr
88	cHex	Cbz	Me
89	cHex	Cbz	Et
90	cHex	Cbz	Pr
91	cHex	Moc	Me
92	cHex	Moc	Et
93	cHex	Moc	Pr
94	cHex	Eoc	Me
95	cHex	Eoc	Et
96	cHex	Eoc	Pr
97	cHex	Ac	Me
98	cHex	Ac	Et
99	cHex	Ac	Pr
100	cHex	PhOCO	Me
101	cHex	PhOCO	Et
102	cHex	PhOCO	Pr
103	cHex	Bzl	Me
104	cHex	Bzl	Et
105	cHex	Bzl	Pr

TABLE 3 — (Id) Compound

No.	R 2	R 3	R 4	X	Y
1	iPr	Boc	Me	MeN	H
2	iPr	Boc	Me	MeN	Cl
3	iPr	Boc	Me	MeN	Br
4	iPr	Boc	Me	MeN	Oct
5	iPr	Boc	Me	MeN	HepO
6	iPr	Boc	Me	MeN	HepCO
7	iPr	Boc	Me	CHCH	Cl
8	iPr	Boc	Me	CHCH	Br
9	iPr	Boc	Me	CHCH	I
10	iPr	Boc	Me	CHCH	Oct
11	iPr	Boc	Me	CHCH	HepO
12	iPr	Boc	Me	CHCH	HepCO
13	iPr	Boc	Et	MeN	H
14	iPr	Boc	Et	MeN	Cl
15	iPr	Boc	Et	MeN	Br
16	iPr	Boc	Et	MeN	Oct
17	iPr	Boc	Et	MeN	HepO
18	iPr	Boc	Et	MeN	HepCO
19	iPr	Boc	Et	CHCH	Cl
20	iPr	Boc	Et	CHCH	Br
21	iPr	Boc	Et	CHCH	I
22	iPr	Boc	Et	CHCH	Oct
23	iPr	Boc	Et	CHCH	HepO
24	iPr	Boc	Et	CHCH	HepCO
25	iPr	Moc	Me	MeN	H
26	iPr	Moc	Me	MeN	Cl
27	iPr	Moc	Me	MeN	Br
28	iPr	Moc	Me	MeN	Oct
29	iPr	Moc	Me	MeN	HepO
30	iPr	Moc	Me	MeN	HepCO
31	iPr	Moc	Me	CHCH	Cl
32	iPr	Moc	Me	CHCH	Br
33	iPr	Moc	Me	CHCH	I
34	iPr	Moc	Me	CHCH	Oct
35	iPr	Moc	Me	CHCH	HepO
36	iPr	Moc	Me	CHCH	HepCO
37	iPr	Moc	Et	MeN	H
38	iPr	Moc	Et	MeN	Cl
39	iPr	Moc	Et	MeN	Br
40	iPr	Moc	Et	MeN	Oct
41	iPr	Moc	Et	MeN	HepO
42	iPr	Moc	Et	MeN	HepCO
43	iPr	Moc	Et	CHCH	Cl
44	iPr	Moc	Et	CHCH	Br
45	iPr	Moc	Et	CHCH	I
46	iPr	Moc	Et	CHCH	Oct
47	iPr	Moc	Et	CHCH	HepO
48	iPr	Moc	Et	CHCH	HepCO
49	iPr	PhOCO	Me	MeN	H
50	iPr	PhOCO	Me	MeN	Cl
51	iPr	PhOCO	Me	MeN	Br
52	iPr	PhOCO	Me	MeN	Oct
53	iPr	PhOCO	Me	MeN	HepO
54	iPr	PhOCO	Me	MeN	HepCO
55	iPr	PhOCO	Me	CHCH	Cl
56	iPr	PhOCO	Me	CHCH	Br
57	iPr	PhOCO	Me	CHCH	I
58	iPr	PhOCO	Me	CHCH	Oct
59	iPr	PhOCO	Me	CHCH	HepO
60	iPr	PhOCO	Me	CHCH	HepCO
61	iPr	PhOCO	Et	MeN	H
62	iPr	PhOCO	Et	MeN	Cl
63	iPr	PhOCO	Et	MeN	Br
64	iPr	PhOCO	Et	MeN	Oct
65	iPr	PhOCO	Et	MeN	HepO
66	iPr	PhOCO	Et	MeN	HepCO
67	iPr	PhOCO	Et	CHCH	Cl
68	iPr	PhOCO	Et	CHCH	Br
69	iPr	PhOCO	Et	CHCH	I
70	iPr	PhOCO	Et	CHCH	Oct
71	iPr	PhOCO	Et	CHCH	HepO
72	iPr	PhOCO	Et	CHCH	HepCO
73	tBu	Boc	Me	MeN	H
74	tBu	Boc	Me	MeN	Cl
75	tBu	Boc	Me	MeN	Br
76	tBu	Boc	Me	MeN	Oct
77	tBu	Boc	Me	MeN	HepO
78	tBu	Boc	Me	MeN	HepCO
79	tBu	Boc	Me	CHCH	Cl
80	tBu	Boc	Me	CHCH	Br
81	tBu	Boc	Me	CHCH	I
82	tBu	Boc	Me	CHCH	Oct
83	tBu	Boc	Me	CHCH	HepO
84	tBu	Boc	Me	CHCH	HepCO
85	tBu	Boc	Et	MeN	H
86	tBu	Boc	Et	MeN	Cl
87	tBu	Boc	Et	MeN	Br
88	tBu	Boc	Et	MeN	Oct
89	tBu	Boc	Et	MeN	HepO
90	tBu	Boc	Et	MeN	HepCO
91	tBu	Boc	Et	CHCH	Cl
92	tBu	Boc	Et	CHCH	Br
93	tBu	Boc	Et	CHCH	I
94	tBu	Boc	Et	CHCH	Oct
95	tBu	Boc	Et	CHCH	HepO
96	tBu	Boc	Et	CHCH	HepCO
97	tBu	Cbz	Me	MeN	H
98	tBu	Cbz	Me	MeN	Cl
99	tBu	Cbz	Me	MeN	Br
100	tBu	Cbz	Me	MeN	Oct
101	tBu	Cbz	Me	MeN	HepO
102	tBu	Cbz	Me	MeN	HepCO
103	tBu	Cbz	Me	CHCH	Cl
104	tBu	Cbz	Me	CHCH	Br
105	tBu	Cbz	Me	CHCH	I
106	tBu	Cbz	Me	CHCH	Oct
107	tBu	Cbz	Me	CHCH	HepO
108	tBu	Cbz	Me	CHCH	HepCO
109	tBu	Cbz	Et	MeN	H
110	tBu	Cbz	Et	MeN	Cl
111	tBu	Cbz	Et	MeN	Br
112	tBu	Cbz	Et	MeN	Oct
113	tBu	Cbz	Et	MeN	HepO
114	tBu	Cbz	Et	MeN	HepCO
115	tBu	Cbz	Et	CHCH	Cl
116	tBu	Cbz	Et	CHCH	Br
117	tBu	Cbz	Et	CHCH	I
118	tBu	Cbz	Et	CHCH	Oct
119	tBu	Cbz	Et	CHCH	HepO
120	tBu	Cbz	Et	CHCH	HepCO
121	tBu	Moc	Me	MeN	H
122	tBu	Moc	Me	MeN	Cl
123	tBu	Moc	Me	MeN	Br
124	tBu	Moc	Me	MeN	Oct
125	tBu	Moc	Me	MeN	HepO
126	tBu	Moc	Me	MeN	HepCO
127	tBu	Moc	Me	CHCH	Cl
128	tBu	Moc	Me	CHCH	Br
129	tBu	Moc	Me	CHCH	I
130	tBu	Moc	Me	CHCH	Oct
131	tBu	Moc	Me	CHCH	HepO
132	tBu	Moc	Me	CHCH	HepCO
133	tBu	Moc	Et	MeN	H
134	tBu	Moc	Et	MeN	Cl
135	tBu	Moc	Et	MeN	Br
136	tBu	Moc	Et	MeN	Oct
137	tBu	Moc	Et	MeN	HepO
138	tBu	Moc	Et	MeN	HepCO
139	tBu	Moc	Et	CHCH	Cl
140	tBu	Moc	Et	CHCH	Br
141	tBu	Moc	Et	CHCH	I
142	tBu	Moc	Et	CHCH	Oct
143	tBu	Moc	Et	CHCH	HepO
144	tBu	Moc	Et	CHCH	HepCO
145	tBu	Eoc	Me	MeN	H
146	tBu	Eoc	Me	MeN	Cl
147	tBu	Eoc	Me	MeN	Br
148	tBu	Eoc	Me	MeN	Oct
149	tBu	Eoc	Me	MeN	HepO
150	tBu	Eoc	Me	MeN	HepCO
151	tBu	Eoc	Me	CHCH	Cl
152	tBu	Eoc	Me	CHCH	Br
153	tBu	Eoc	Me	CHCH	I
154	tBu	Eoc	Me	CHCH	Oct
155	tBu	Eoc	Me	CHCH	HepO
156	tBu	Eoc	Me	CHCH	HepCO
157	tBu	Eoc	Et	MeN	H
158	tBu	Eoc	Et	MeN	Cl
159	tBu	Eoc	Et	MeN	Br
160	tBu	Eoc	Et	MeN	Oct
161	tBu	Eoc	Et	MeN	HepO
162	tBu	Eoc	Et	MeN	HepCO
163	tBu	Eoc	Et	CHCH	Cl
164	tBu	Eoc	Et	CHCH	Br
165	tBu	Eoc	Et	CHCH	I
166	tBu	Eoc	Et	CHCH	Oct
167	tBu	Eoc	Et	CHCH	HepO
168	tBu	Eoc	Et	CHCH	HepCO
169	tBu	PhOCO	Me	MeN	H
170	tBu	PhOCO	Me	MeN	Cl
171	tBu	PhOCO	Me	MeN	Br
172	tBu	PhOCO	Me	MeN	Oct
173	tBu	PhOCO	Me	MeN	HepO
174	tBu	PhOCO	Me	MeN	HepCO
175	tBu	PhOCO	Me	CHCH	Cl
176	tBu	PhOCO	Me	CHCH	Br
177	tBu	PhOCO	Me	CHCH	I
178	tBu	PhOCO	Me	CHCH	Oct
179	tBu	PhOCO	Me	CHCH	HepO
180	tBu	PhOCO	Me	CHCH	HepCO
181	tBu	PhOCO	Et	MeN	H
182	tBu	PhOCO	Et	MeN	Cl
183	tBu	PhOCO	Et	MeN	Br
184	tBu	PhOCO	Et	MeN	Oct
185	tBu	PhOCO	Et	MeN	HepO
186	tBu	PhOCO	Et	MeN	HepCO
187	tBu	PhOCO	Et	CHCH	Cl
188	tBu	PhOCO	Et	CHCH	Br
189	tBu	PhOCO	Et	CHCH	I
190	tBu	PhOCO	Et	CHCH	Oct
191	tBu	PhOCO	Et	CHCH	HepO
192	tBu	PhOCO	Et	CHCH	HepCO
193	tBu	Ac	Me	MeN	H
194	tBu	Ac	Me	MeN	Cl
195	tBu	Ac	Me	MeN	Br
196	tBu	Ac	Me	MeN	Oct
197	tBu	Ac	Me	MeN	HepO
198	tBu	Ac	Me	MeN	HepCO
199	tBu	Ac	Me	CHCH	Cl
200	tBu	Ac	Me	CHCH	Br
201	tBu	Ac	Me	CHCH	I
202	tBu	Ac	Me	CHCH	Oct
203	tBu	Ac	Me	CHCH	HepO
204	tBu	Ac	Me	CHCH	HepCO
205	tBu	Ac	Et	MeN	H
206	tBu	Ac	Et	MeN	Cl
207	tBu	Ac	Et	MeN	Br
208	tBu	Ac	Et	MeN	Oct
209	tBu	Ac	Et	MeN	HepO
210	tBu	Ac	Et	MeN	HepCO
211	tBu	Ac	Et	CHCH	Cl
212	tBu	Ac	Et	CHCH	Br
213	tBu	Ac	Et	CHCH	I
214	tBu	Ac	Et	CHCH	Oct
215	tBu	Ac	Et	CHCH	HepO
216	tBu	Ac	Et	CHCH	HepCO
217	tBu	Bzl	Me	MeN	H
218	tBu	Bzl	Me	MeN	Cl
219	tBu	Bzl	Me	MeN	Br
220	tBu	Bzl	Me	MeN	Oct
221	tBu	Bzl	Me	MeN	HepO
222	tBu	Bzl	Me	MeN	HepCO
223	tBu	Bzl	Me	CHCH	Cl
224	tBu	Bzl	Me	CHCH	Br
225	tBu	Bzl	Me	CHCH	I
226	tBu	Bzl	Me	CHCH	Oct
227	tBu	Bzl	Me	CHCH	HepO
228	tBu	Bzl	Me	CHCH	HepCO
229	tBu	Bzl	Et	MeN	H
230	tBu	Bzl	Et	MeN	Cl
231	tBu	Bzl	Et	MeN	Br
232	tBu	Bzl	Et	MeN	Oct
233	tBu	Bzl	Et	MeN	HepO
234	tBu	Bzl	Et	MeN	HepCO
235	tBu	Bzl	Et	CHCH	Cl
236	tBu	Bzl	Et	CHCH	Br
237	tBu	Bzl	Et	CHCH	I
238	tBu	Bzl	Et	CHCH	Oct
239	tBu	Bzl	Et	CHCH	HepO
240	tBu	Bzl	Et	CHCH	HepCO
241	Et 2 CH	Boc	Me	MeN	H
242	Et 2 CH	Boc	Me	MeN	Cl
243	Et 2 CH	Boc	Me	MeN	Br
244	Et 2 CH	Boc	Me	MeN	Oct
245	Et 2 CH	Boc	Me	MeN	HepO
246	Et 2 CH	Boc	Me	MeN	HepCO
247	Et 2 CH	Boc	Me	CHCH	Cl
248	Et 2 CH	Boc	Me	CHCH	Br
249	Et 2 CH	Boc	Me	CHCH	I
250	Et 2 CH	Boc	Me	CHCH	Oct
251	Et 2 CH	Boc	Me	CHCH	HepO
252	Et 2 CH	Boc	Me	CHCH	HepCO
253	Et 2 CH	Boc	Et	MeN	H
254	Et 2 CH	Boc	Et	MeN	Cl
255	Et 2 CH	Boc	Et	MeN	Br
256	Et 2 CH	Boc	Et	MeN	Oct
257	Et 2 CH	Boc	Et	MeN	HepO
258	Et 2 CH	Boc	Et	MeN	HepCO
259	Et 2 CH	Boc	Et	CHCH	Cl
260	Et 2 CH	Boc	Et	CHCH	Br
261	Et 2 CH	Boc	Et	CHCH	I
262	Et 2 CH	Boc	Et	CHCH	Oct
263	Et 2 CH	Boc	Et	CHCH	HepO
264	Et 2 CH	Boc	Et	CHCH	HepCO
265	Et 2 CH	Moc	Me	MeN	H
266	Et 2 CH	Moc	Me	MeN	Cl
267	Et 2 CH	Moc	Me	MeN	Br
268	Et 2 CH	Moc	Me	MeN	Oct
269	Et 2 CH	Moc	Me	MeN	HepO
270	Et 2 CH	Moc	Me	MeN	HepCO
271	Et 2 CH	Moc	Me	CHCH	Cl
272	Et 2 CH	Moc	Me	CHCH	Br
273	Et 2 CH	Moc	Me	CHCH	I
274	Et 2 CH	Moc	Me	CHCH	Oct
275	Et 2 CH	Moc	Me	CHCH	HepO
276	Et 2 CH	Moc	Me	CHCH	HepCO
277	Et 2 CH	Moc	Et	MeN	H
278	Et 2 CH	Moc	Et	MeN	Cl
279	Et 2 CH	Moc	Et	MeN	B
280	Et 2 CH	Moc	Et	MeN	Oct
281	Et 2 CH	Moc	Et	MeN	HepO
282	Et 2 CH	Moc	Et	MeN	HepCO
283	Et 2 CH	Moc	Et	CHCH	Cl
284	Et 2 CH	Moc	Et	CHCH	Br
285	Et 2 CH	Moc	Et	CHCH	I
286	Et 2 CH	Moc	Et	CHCH	Oct
287	Et 2 CH	Moc	Et	CHCH	HepO
288	Et 2 CH	Moc	Et	CHCH	HepCO
289	Et 2 CH	PhOCO	Me	MeN	H
290	Et 2 CH	PhOCO	Me	MeN	Cl
291	Et 2 CH	PhOCO	Me	MeN	Br
292	Et 2 CH	PhOCO	Me	MeN	Oct
293	Et 2 CH	PhOCO	Me	MeN	HepO
294	Et 2 CH	PhOCO	Me	MeN	HepCO
295	Et 2 CH	PhOCO	Me	CHCH	Cl
296	Et 2 CH	PhOCO	Me	CHCH	Br
297	Et 2 CH	PhOCO	Me	CHCH	I
298	Et 2 CH	PhOCO	Me	CHCH	Oct
299	Et 2 CH	PhOCO	Me	CHCH	HepO
300	Et 2 CH	PhOCO	Me	CHCH	HepCO
301	Et 2 CH	PhOCO	Et	MeN	H
302	Et 2 CH	PhOCO	Et	MeN	Cl
303	Et 2 CH	PhOCO	Et	MeN	Br
304	Et 2 CH	PhOCO	Et	MeN	Oct
305	Et 2 CH	PhOCO	Et	MeN	HepO
306	Et 2 CH	PhOCO	Et	MeN	HepCO
307	Et 2 CH	PhOCO	Et	CHCH	Cl
308	Et 2 CH	PhOCO	Et	CHCH	Br
309	Et 2 CH	PhOCO	Et	CHCH	I
310	Et 2 CH	PhOCO	Et	CHCH	Oct
311	Et 2 CH	PhOCO	Et	CHCH	HepO
312	Et 2 CH	PhOCO	Et	CHCH	HepCO
313	Ph	Boc	Me	MeN	H
314	Ph	Boc	Me	MeN	Cl
315	Ph	Boc	Me	MeN	Br
316	Ph	Boc	Me	MeN	Oct
317	Ph	Boc	Me	MeN	HepO
318	Ph	Boc	Me	MeN	HepCO
319	Ph	Boc	Me	CHCH	Cl
320	Ph	Boc	Me	CHCH	Br
321	Ph	Boc	Me	CHCH	I
322	Ph	Boc	Me	CHCH	Oct
323	Ph	Boc	Me	CHCH	HepO
324	Ph	Boc	Me	CHCH	HepCO
325	Ph	Boc	Et	MeN	H
326	Ph	Boc	Et	MeN	Cl
327	Ph	Boc	Et	MeN	Br
328	Ph	Boc	Et	MeN	Oct
329	Ph	Boc	Et	MeN	HepO
330	Ph	Boc	Et	MeN	HepCO
331	Ph	Boc	Et	CHCH	Cl
332	Ph	Boc	Et	CHCH	Br
333	Ph	Boc	Et	CHCH	I
334	Ph	Boc	Et	CHCH	Oct
335	Ph	Boc	Et	CHCH	HepO
336	Ph	Boc	Et	CHCH	HepCO
337	Ph	Moc	Me	MeN	H
338	Ph	Moc	Me	MeN	Cl
339	Ph	Moc	Me	MeN	Br
340	Ph	Moc	Me	MeN	Oct
341	Ph	Moc	Me	MeN	HepO
342	Ph	Moc	Me	MeN	HepCO
343	Ph	Moc	Me	CHCH	Cl
344	Ph	Moc	Me	CHCH	Br
345	Ph	Moc	Me	CHCH	I
346	Ph	Moc	Me	CHCH	Oct
347	Ph	Moc	Me	CHCH	HepO
348	Ph	Moc	Me	CHCH	HepCO
349	Ph	Moc	Et	MeN	H
350	Ph	Moc	Et	MeN	Cl
351	Ph	Moc	Et	MeN	Br
352	Ph	Moc	Et	MeN	Oct
353	Ph	Moc	Et	MeN	HepO
354	Ph	Moc	Et	MeN	HepCO
355	Ph	Moc	Et	CHCH	Cl
356	Ph	Moc	Et	CHCH	Br
357	Ph	Moc	Et	CHCH	I
358	Ph	Moc	Et	CHCH	Oct
359	Ph	Moc	Et	CHCH	HepO
360	Ph	Moc	Et	CHCH	HepCO
361	Ph	PhOCO	Me	MeN	H
362	Ph	PhOCO	Me	MeN	Cl
363	Ph	PhOCO	Me	MeN	Br
364	Ph	PhOCO	Me	MeN	Oct
365	Ph	PhOCO	Me	MeN	HepO
366	Ph	PhOCO	Me	MeN	HepCO
367	Ph	PhOCO	Me	CHCH	Cl
368	Ph	PhOCO	Me	CHCH	Br
369	Ph	PhOCO	Me	CHCH	I
370	Ph	PhOCO	Me	CHCH	Oct
371	Ph	PhOCO	Me	CHCH	HepO
372	Ph	PhOCO	Me	CHCH	HepCO
373	Ph	PhOCO	Et	MeN	H
374	Ph	PhOCO	Et	MeN	Cl
375	Ph	PhOCO	Et	MeN	Br
376	Ph	PhOCO	Et	MeN	Oct
377	Ph	PhOCO	Et	MeN	HepO
378	Ph	PhOCO	Et	MeN	HepCO
379	Ph	PhOCO	Et	CHCH	Cl
380	Ph	PhOCO	Et	CHCH	Br
381	Ph	PhOCO	Et	CHCH	I
382	Ph	PhOCO	Et	CHCH	Oct
383	Ph	PhOCO	Et	CHCH	HepO
384	Ph	PhOCO	Et	CHCH	HepCO

Claims as granted

17 claims

Classifications

4 codes

IPC · International Patent Classification

Section C — Chemistry; metallurgy

C07D263/02
C07D413/00

USPC · US Patent Classification

548/215548/100

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this application are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoom

USPTOApplicanthover for detail · click to open

Pendency

3.6 y

1,329 days filing → grant

Office actions

after a restriction

Responses

no RCE

Interviews

examiner interview summaries

Examiner

Kamal A Saeed

art unit 1626 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 19 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Documents

Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.

Chain of title

⤢ drag to zoom

Titlehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.